<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 39.96?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?subarticle pcbi.1010052.r001?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id>
    <journal-id journal-id-type="iso-abbrev">PLoS Comput Biol</journal-id>
    <journal-id journal-id-type="publisher-id">plos</journal-id>
    <journal-title-group>
      <journal-title>PLoS Computational Biology</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1553-734X</issn>
    <issn pub-type="epub">1553-7358</issn>
    <publisher>
      <publisher-name>Public Library of Science</publisher-name>
      <publisher-loc>San Francisco, CA USA</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9524643</article-id>
    <article-id pub-id-type="pmid">36126074</article-id>
    <article-id pub-id-type="doi">10.1371/journal.pcbi.1010052</article-id>
    <article-id pub-id-type="publisher-id">PCOMPBIOL-D-22-00462</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Research Article</subject>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Physiology</subject>
          <subj-group>
            <subject>Immune Physiology</subject>
            <subj-group>
              <subject>Antibodies</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Immunology</subject>
          <subj-group>
            <subject>Immune System Proteins</subject>
            <subj-group>
              <subject>Antibodies</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Medicine and Health Sciences</subject>
        <subj-group>
          <subject>Immunology</subject>
          <subj-group>
            <subject>Immune System Proteins</subject>
            <subj-group>
              <subject>Antibodies</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Biochemistry</subject>
          <subj-group>
            <subject>Proteins</subject>
            <subj-group>
              <subject>Immune System Proteins</subject>
              <subj-group>
                <subject>Antibodies</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Microbiology</subject>
          <subj-group>
            <subject>Medical Microbiology</subject>
            <subj-group>
              <subject>Microbial Pathogens</subject>
              <subj-group>
                <subject>Viral Pathogens</subject>
                <subj-group>
                  <subject>Immunodeficiency Viruses</subject>
                  <subj-group>
                    <subject>HIV</subject>
                    <subj-group>
                      <subject>HIV-1</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Medicine and Health Sciences</subject>
        <subj-group>
          <subject>Pathology and Laboratory Medicine</subject>
          <subj-group>
            <subject>Pathogens</subject>
            <subj-group>
              <subject>Microbial Pathogens</subject>
              <subj-group>
                <subject>Viral Pathogens</subject>
                <subj-group>
                  <subject>Immunodeficiency Viruses</subject>
                  <subj-group>
                    <subject>HIV</subject>
                    <subj-group>
                      <subject>HIV-1</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Organisms</subject>
          <subj-group>
            <subject>Viruses</subject>
            <subj-group>
              <subject>Viral Pathogens</subject>
              <subj-group>
                <subject>Immunodeficiency Viruses</subject>
                <subj-group>
                  <subject>HIV</subject>
                  <subj-group>
                    <subject>HIV-1</subject>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Organisms</subject>
          <subj-group>
            <subject>Viruses</subject>
            <subj-group>
              <subject>Immunodeficiency Viruses</subject>
              <subj-group>
                <subject>HIV</subject>
                <subj-group>
                  <subject>HIV-1</subject>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and life sciences</subject>
        <subj-group>
          <subject>Organisms</subject>
          <subj-group>
            <subject>Viruses</subject>
            <subj-group>
              <subject>RNA viruses</subject>
              <subj-group>
                <subject>Retroviruses</subject>
                <subj-group>
                  <subject>Lentivirus</subject>
                  <subj-group>
                    <subject>HIV</subject>
                    <subj-group>
                      <subject>HIV-1</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Microbiology</subject>
          <subj-group>
            <subject>Medical Microbiology</subject>
            <subj-group>
              <subject>Microbial Pathogens</subject>
              <subj-group>
                <subject>Viral Pathogens</subject>
                <subj-group>
                  <subject>Retroviruses</subject>
                  <subj-group>
                    <subject>Lentivirus</subject>
                    <subj-group>
                      <subject>HIV</subject>
                      <subj-group>
                        <subject>HIV-1</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Medicine and Health Sciences</subject>
        <subj-group>
          <subject>Pathology and Laboratory Medicine</subject>
          <subj-group>
            <subject>Pathogens</subject>
            <subj-group>
              <subject>Microbial Pathogens</subject>
              <subj-group>
                <subject>Viral Pathogens</subject>
                <subj-group>
                  <subject>Retroviruses</subject>
                  <subj-group>
                    <subject>Lentivirus</subject>
                    <subj-group>
                      <subject>HIV</subject>
                      <subj-group>
                        <subject>HIV-1</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Organisms</subject>
          <subj-group>
            <subject>Viruses</subject>
            <subj-group>
              <subject>Viral Pathogens</subject>
              <subj-group>
                <subject>Retroviruses</subject>
                <subj-group>
                  <subject>Lentivirus</subject>
                  <subj-group>
                    <subject>HIV</subject>
                    <subj-group>
                      <subject>HIV-1</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Medicine and Health Sciences</subject>
        <subj-group>
          <subject>Medical Conditions</subject>
          <subj-group>
            <subject>Tropical Diseases</subject>
            <subj-group>
              <subject>Neglected Tropical Diseases</subject>
              <subj-group>
                <subject>Dengue Fever</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Medicine and Health Sciences</subject>
        <subj-group>
          <subject>Medical Conditions</subject>
          <subj-group>
            <subject>Infectious Diseases</subject>
            <subj-group>
              <subject>Viral Diseases</subject>
              <subj-group>
                <subject>Dengue Fever</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Medicine and Health Sciences</subject>
        <subj-group>
          <subject>Medical Conditions</subject>
          <subj-group>
            <subject>Infectious Diseases</subject>
            <subj-group>
              <subject>Viral Diseases</subject>
              <subj-group>
                <subject>Covid 19</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Research and Analysis Methods</subject>
        <subj-group>
          <subject>Database and Informatics Methods</subject>
          <subj-group>
            <subject>Bioinformatics</subject>
            <subj-group>
              <subject>Sequence Analysis</subject>
              <subj-group>
                <subject>Sequence Motif Analysis</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Computer and Information Sciences</subject>
        <subj-group>
          <subject>Data Management</subject>
          <subj-group>
            <subject>Data Visualization</subject>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and life sciences</subject>
        <subj-group>
          <subject>Organisms</subject>
          <subj-group>
            <subject>Viruses</subject>
            <subj-group>
              <subject>RNA viruses</subject>
              <subj-group>
                <subject>Coronaviruses</subject>
                <subj-group>
                  <subject>SARS coronavirus</subject>
                  <subj-group>
                    <subject>SARS CoV 2</subject>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and life sciences</subject>
        <subj-group>
          <subject>Microbiology</subject>
          <subj-group>
            <subject>Medical microbiology</subject>
            <subj-group>
              <subject>Microbial pathogens</subject>
              <subj-group>
                <subject>Viral pathogens</subject>
                <subj-group>
                  <subject>Coronaviruses</subject>
                  <subj-group>
                    <subject>SARS coronavirus</subject>
                    <subj-group>
                      <subject>SARS CoV 2</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Medicine and health sciences</subject>
        <subj-group>
          <subject>Pathology and laboratory medicine</subject>
          <subj-group>
            <subject>Pathogens</subject>
            <subj-group>
              <subject>Microbial pathogens</subject>
              <subj-group>
                <subject>Viral pathogens</subject>
                <subj-group>
                  <subject>Coronaviruses</subject>
                  <subj-group>
                    <subject>SARS coronavirus</subject>
                    <subj-group>
                      <subject>SARS CoV 2</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and life sciences</subject>
        <subj-group>
          <subject>Organisms</subject>
          <subj-group>
            <subject>Viruses</subject>
            <subj-group>
              <subject>Viral pathogens</subject>
              <subj-group>
                <subject>Coronaviruses</subject>
                <subj-group>
                  <subject>SARS coronavirus</subject>
                  <subj-group>
                    <subject>SARS CoV 2</subject>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Evolutionary Biology</subject>
          <subj-group>
            <subject>Evolutionary Processes</subject>
            <subj-group>
              <subject>Convergent Evolution</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>AIRRscape: An interactive tool for exploring B-cell receptor repertoires and antibody responses</article-title>
      <alt-title alt-title-type="running-head">AIRRscape: An interactive tool for exploring antibody repertoires</alt-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6930-9645</contrib-id>
        <name>
          <surname>Waltari</surname>
          <given-names>Eric</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
        <role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
        <role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
        <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
        <role content-type="http://credit.niso.org/contributor-roles/software/">Software</role>
        <role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role>
        <role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="cor001" ref-type="corresp">*</xref>
        <xref rid="aff001" ref-type="aff"/>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3292-7703</contrib-id>
        <name>
          <surname>Nafees</surname>
          <given-names>Saba</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/software/">Software</role>
        <role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="aff001" ref-type="aff"/>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1942-5175</contrib-id>
        <name>
          <surname>McCutcheon</surname>
          <given-names>Krista M.</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role>
        <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="currentaff001" ref-type="author-notes">
          <sup>¤</sup>
        </xref>
        <xref rid="aff001" ref-type="aff"/>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7849-6320</contrib-id>
        <name>
          <surname>Wong</surname>
          <given-names>Joan</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role>
        <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
        <role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="aff001" ref-type="aff"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2998-9735</contrib-id>
        <name>
          <surname>Pak</surname>
          <given-names>John E.</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
        <role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role>
        <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
        <role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="cor001" ref-type="corresp">*</xref>
        <xref rid="aff001" ref-type="aff"/>
      </contrib>
    </contrib-group>
    <aff id="aff001">
      <addr-line>Chan Zuckerberg Biohub, San Francisco, California, United States of America</addr-line>
    </aff>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Yaari</surname>
          <given-names>Gur</given-names>
        </name>
        <role>Editor</role>
        <xref rid="edit1" ref-type="aff"/>
      </contrib>
    </contrib-group>
    <aff id="edit1">
      <addr-line>Bar Ilan University, ISRAEL</addr-line>
    </aff>
    <author-notes>
      <fn fn-type="COI-statement" id="coi001">
        <p>The authors have declared that no competing interests exist.</p>
      </fn>
      <fn fn-type="current-aff" id="currentaff001">
        <label>¤</label>
        <p>Current address: Immune-Onc Therapeutics Inc, Palo Alto, California, United States of America</p>
      </fn>
      <corresp id="cor001">* E-mail: <email>eric.waltari@czbiohub.org</email> (EW); <email>john.pak@czbiohub.org</email> (JEP)</corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>20</day>
      <month>9</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="collection">
      <month>9</month>
      <year>2022</year>
    </pub-date>
    <volume>18</volume>
    <issue>9</issue>
    <elocation-id>e1010052</elocation-id>
    <history>
      <date date-type="received">
        <day>23</day>
        <month>3</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>4</day>
        <month>9</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2022 Waltari et al</copyright-statement>
      <copyright-year>2022</copyright-year>
      <copyright-holder>Waltari et al</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <self-uri content-type="pdf" xlink:href="pcbi.1010052.pdf"/>
    <abstract>
      <p>The sequencing of antibody repertoires of B-cells at increasing coverage and depth has led to the identification of vast numbers of immunoglobulin heavy and light chains. However, the size and complexity of these Adaptive Immune Receptor Repertoire sequencing (AIRR-seq) datasets makes it difficult to perform exploratory analyses. To aid in data exploration, we have developed AIRRscape, an R Shiny-based interactive web browser application that enables B-cell receptor (BCR) and antibody feature discovery through comparisons among multiple repertoires. Using AIRR-seq data as input, AIRRscape starts by aggregating and sorting repertoires into interactive and explorable bins of germline V-gene, germline J-gene, and CDR3 length, providing a high-level view of the entire repertoire. Interesting subsets of repertoires can be quickly identified and selected, and then network topologies of CDR3 motifs can be generated for further exploration. Here we demonstrate AIRRscape using patient BCR repertoires and sequences of published monoclonal antibodies to investigate patterns of humoral immunity to three viral pathogens: SARS-CoV-2, HIV-1, and DENV (dengue virus). AIRRscape reveals convergent antibody sequences among datasets for all three pathogens, although HIV-1 antibody datasets display limited convergence and idiosyncratic responses. We have made AIRRscape available as a web-based Shiny application, along with code on GitHub to encourage its open development and use by immuno-informaticians, virologists, immunologists, vaccine developers, and other scientists that are interested in exploring and comparing multiple immune receptor repertoires.</p>
    </abstract>
    <abstract abstract-type="summary">
      <title>Author summary</title>
      <p>Technological advances in next generation sequencing have allowed for broad experimental sampling of immune repertoires, providing insight into how our immune system responds to infection, vaccination, autoimmunity, and cancer. The scale of these “big data”, however, make it difficult to bioinformatically extract the key sequence features that are shared across multiple repertoires. With AIRRscape, we enable large-scale immune repertoire visualization and analysis that requires no knowledge of the command line or advanced programming. By providing the community with an open-source, interactive, and user-friendly interface, we reduce the barriers to exploring immune repertoires at scale. We demonstrate the use of AIRRscape to characterize features of immune responses to viral infection that are shared across multiple repertoire datasets.</p>
    </abstract>
    <funding-group>
      <award-group id="award001">
        <funding-source>
          <institution>Chan Zuckerberg Biohub</institution>
        </funding-source>
      </award-group>
      <funding-statement>This work was supported by the Chan Zuckerberg Biohub. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
    </funding-group>
    <counts>
      <fig-count count="8"/>
      <table-count count="3"/>
      <page-count count="22"/>
    </counts>
    <custom-meta-group>
      <custom-meta>
        <meta-name>PLOS Publication Stage</meta-name>
        <meta-value>vor-update-to-uncorrected-proof</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>Publication Update</meta-name>
        <meta-value>2022-09-30</meta-value>
      </custom-meta>
      <custom-meta id="data-availability">
        <meta-name>Data Availability</meta-name>
        <meta-value>All AIRRscape code and data loaded for visualization as well as code for processing datasets are available on a GitHub repository at <ext-link xlink:href="https://github.com/czbiohub/AIRRscape" ext-link-type="uri">https://github.com/czbiohub/AIRRscape</ext-link>, and we have used Zenodo to assign a DOI to the repository: 10.5281/zenodo.7080165. The online version of AIRRscape is also available at <ext-link xlink:href="https://airrscape.czbiohub.org" ext-link-type="uri">https://airrscape.czbiohub.org</ext-link>.</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
  <notes>
    <title>Data Availability</title>
    <p>All AIRRscape code and data loaded for visualization as well as code for processing datasets are available on a GitHub repository at <ext-link xlink:href="https://github.com/czbiohub/AIRRscape" ext-link-type="uri">https://github.com/czbiohub/AIRRscape</ext-link>, and we have used Zenodo to assign a DOI to the repository: 10.5281/zenodo.7080165. The online version of AIRRscape is also available at <ext-link xlink:href="https://airrscape.czbiohub.org" ext-link-type="uri">https://airrscape.czbiohub.org</ext-link>.</p>
  </notes>
</front>
<body>
  <sec sec-type="intro" id="sec001">
    <title>1. Introduction</title>
    <p>Individual B-cell receptor (BCR) repertoires have exceptional diversity, estimated to be greater than 10<sup>9</sup> in a single adult [<xref rid="pcbi.1010052.ref001" ref-type="bibr">1</xref>,<xref rid="pcbi.1010052.ref002" ref-type="bibr">2</xref>]. Improvements in sequencing capability over the past twenty years have allowed a wider sampling of BCR sequences to be uncovered, e.g. [<xref rid="pcbi.1010052.ref003" ref-type="bibr">3</xref>–<xref rid="pcbi.1010052.ref005" ref-type="bibr">5</xref>]. These adaptive immune receptor response sequence (AIRR-seq) datasets can offer a complex and information-rich glimpse into B-cell immune responses to vaccination and infection. For example, with analyses of AIRR-seq data comes an increasing recognition that convergence among BCR repertoires, sometimes termed ‘public’ clonotypes [<xref rid="pcbi.1010052.ref001" ref-type="bibr">1</xref>,<xref rid="pcbi.1010052.ref002" ref-type="bibr">2</xref>,<xref rid="pcbi.1010052.ref006" ref-type="bibr">6</xref>,<xref rid="pcbi.1010052.ref007" ref-type="bibr">7</xref>], is important for understanding the humoral immune response to natural infections and for improving vaccine design.</p>
    <p>The size of AIRR-seq datasets can make it challenging to visualize the BCR sequence features of individual repertoires, let alone of multiple repertoires concurrently. Several groups have developed metrics to assess similarity among entire BCR repertoires [<xref rid="pcbi.1010052.ref008" ref-type="bibr">8</xref>,<xref rid="pcbi.1010052.ref009" ref-type="bibr">9</xref>], but few open-source tools enable facile, multi-dimensional visualization and exploration of these repertoires. An overview of existing tools and their features [<xref rid="pcbi.1010052.ref010" ref-type="bibr">10</xref>–<xref rid="pcbi.1010052.ref021" ref-type="bibr">21</xref>] is provided in <xref rid="pcbi.1010052.t001" ref-type="table">Table 1</xref>. Notable examples of higher-level BCR repertoire visualizations (e.g. for features such as V-gene and J-gene usage, CDR3 length, and CDR3 amino acid sequence motifs) include Circos plots [<xref rid="pcbi.1010052.ref022" ref-type="bibr">22</xref>], radial phylogenies [<xref rid="pcbi.1010052.ref023" ref-type="bibr">23</xref>], and clouds summarizing clonotype networks [<xref rid="pcbi.1010052.ref024" ref-type="bibr">24</xref>]. While powerful in offering a global overview of AIRR-seq data, these methods are not amenable to interactive exploration, in particular to uncover and display antibody convergence.</p>
    <table-wrap position="float" id="pcbi.1010052.t001">
      <object-id pub-id-type="doi">10.1371/journal.pcbi.1010052.t001</object-id>
      <label>Table 1</label>
      <caption>
        <title>Open-source tools for comparing and visualizing BCR repertoires.</title>
      </caption>
      <alternatives>
        <graphic xlink:href="pcbi.1010052.t001" id="pcbi.1010052.t001g" position="float"/>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" valign="middle" span="1"/>
            <col align="left" valign="middle" span="1"/>
            <col align="left" valign="middle" span="1"/>
            <col align="left" valign="middle" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th align="center" rowspan="1" colspan="1">Tool</th>
              <th align="center" rowspan="1" colspan="1">Summary</th>
              <th align="center" rowspan="1" colspan="1">Features</th>
              <th align="center" rowspan="1" colspan="1">Reference</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">AIRRscape</td>
              <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">Web-based interactive tool for exploring B-cell receptor repertoires</td>
              <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">Enables <bold>easy input</bold> of AIRR-seq datasets; <bold>simultaneously visualizes</bold> hundreds of thousands of sequences and networks of CDR3 motifs for analysis of convergence</td>
              <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">This study</td>
            </tr>
            <tr>
              <td align="center" rowspan="1" colspan="1">AncesTree</td>
              <td align="center" rowspan="1" colspan="1">Interactive immunoglobulin lineage tree visualizer</td>
              <td align="center" rowspan="1" colspan="1">Enables exploration of antibody clonal lineages processed following AIRR Community standards using a Java-based GUI</td>
              <td align="center" rowspan="1" colspan="1">10</td>
            </tr>
            <tr>
              <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">ASAP</td>
              <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">Web server for AIRR-seq analysis pipeline</td>
              <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">Processes and visualizes multiple repertoires starting from paired fastq files; outputs plots of somatic hypermutation, VDJ gene usage, &amp; clonal expansion</td>
              <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">11</td>
            </tr>
            <tr>
              <td align="center" rowspan="1" colspan="1">BRrepertoire</td>
              <td align="center" rowspan="1" colspan="1">Web server for large-scale statistical analyses of repertoire data</td>
              <td align="center" rowspan="1" colspan="1">Accepts web-based inputs from IMGT output; focuses on plots of physico-chemical properties</td>
              <td align="center" rowspan="1" colspan="1">12</td>
            </tr>
            <tr>
              <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">immunarch</td>
              <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">R package for analysis of T-cell receptor and B-cell receptor repertoires</td>
              <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">Accepts multiple input data types; generates many exploratory plot types using R commands</td>
              <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">13</td>
            </tr>
            <tr>
              <td align="center" rowspan="1" colspan="1">immuneREF</td>
              <td align="center" rowspan="1" colspan="1">R package for analysis of repertoire similarity on a one-to-one, one-to-many, and many-to-many scale</td>
              <td align="center" rowspan="1" colspan="1">Compares multiple repertoires processed via AIRR Community standards; visualizations include repertoire clustering by similarity and comparison of CDR3 amino acid occurrence and VJ usage among repertoires</td>
              <td align="center" rowspan="1" colspan="1">14</td>
            </tr>
            <tr>
              <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">Olmsted</td>
              <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">Dockerized application for B-cell repertoire and clonal family tree exploration</td>
              <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">Visualizes clonal lineages after clustering and processing of AIRR-seq data in JSON format; enables interactive exploration of clonotype phylogenies and amino acid changes</td>
              <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">15</td>
            </tr>
            <tr>
              <td align="center" rowspan="1" colspan="1">PASA</td>
              <td align="center" rowspan="1" colspan="1">Web server for analysis and integration of data obtained from proteomics of serum antibodies</td>
              <td align="center" rowspan="1" colspan="1">Enables exploration of proteomics data obtained via raw mass spectrometry data files from LC-MS/MS</td>
              <td align="center" rowspan="1" colspan="1">16</td>
            </tr>
            <tr>
              <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">sumrep</td>
              <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">R package for immune receptor repertoire comparison and model validation</td>
              <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">Compares multiple repertoires and outputs multiple similarity indices; creates plots of similarity distributions</td>
              <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">17</td>
            </tr>
            <tr>
              <td align="center" rowspan="1" colspan="1">VDJbase</td>
              <td align="center" rowspan="1" colspan="1">AIRR-seq genotype and haplotype database</td>
              <td align="center" rowspan="1" colspan="1">Has interactive modules for analysis of published AIRR-seq data including haplotype, gene, and allele usage; produces reports</td>
              <td align="center" rowspan="1" colspan="1">18</td>
            </tr>
            <tr>
              <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">VDJServer</td>
              <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">Free, scalable web-based pipeline for immune repertoire analysis</td>
              <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">Processes and visualizes repertoires starting from fastq files; outputs plots of somatic hypermutation, gene usage, clonal abundance, and diversity &amp; selection measures</td>
              <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">19</td>
            </tr>
            <tr>
              <td align="center" rowspan="1" colspan="1">VDJtools</td>
              <td align="center" rowspan="1" colspan="1">Software suite for analysis of T-cell receptor repertoires</td>
              <td align="center" rowspan="1" colspan="1">Processes and visualizes T-cell receptor repertoire datasets</td>
              <td align="center" rowspan="1" colspan="1">20</td>
            </tr>
            <tr>
              <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">VDJviz</td>
              <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">Web tool for browsing and analyzing B-cell and T-cell receptor repertoires</td>
              <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">Uses VDJtools API; has interactive plots of VJ usage, clonal expansion, &amp; rarefaction curves; online demo allows for analysis of up to 25 samples of 10,000 clonotypes each</td>
              <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">21</td>
            </tr>
          </tbody>
        </table>
      </alternatives>
    </table-wrap>
    <p>To enable simultaneous interactive visualization of multiple BCR repertoires and in-depth data exploration, we have developed an open-source tool called AIRRscape. Analysis using AIRRscape begins with the generation of sequence feature heatmaps, which can span both individual or combined AIRR-seq datasets. Visual comparison of these heatmaps in their entirety provides a simple and intuitive global overview of differences in three coupled AIRR-seq dataset features: 1) V- and J-gene usage; 2) CDR3 length, and 3) either somatic hypermutation (SHM) or sequence read count. AIRRscape enables extraction of all sequences that fit a particular set of features from the heatmap (individual or combined datasets) into bins for finer scale local analysis. Topologies or phylogenetic networks of CDRH3 or CDRL3 amino acid motifs can be generated, on the fly, to examine clonotypes and study antibody convergence among multiple studies and patients. Recognizing the lack of consensus on how to define clonal lineages [<xref rid="pcbi.1010052.ref002" ref-type="bibr">2</xref>], we allow users to select from a range of CDR3 identity thresholds to define and visualize antibody convergence. AIRRscape uses R Shiny [<xref rid="pcbi.1010052.ref025" ref-type="bibr">25</xref>], and we have deployed it at <ext-link xlink:href="https://airrscape.czbiohub.org/" ext-link-type="uri">https://airrscape.czbiohub.org</ext-link>. Thus, it can be easily used on any web browser without advanced programming or command-line expertise.</p>
    <p>Here we use AIRRscape to examine collections of antibodies and BCR repertoires from three types of viral infections to address several questions. For SARS-CoV-2: how representative are published antibodies relative to healthy and COVID-19 patient repertoires, and how common are convergent antibody responses [<xref rid="pcbi.1010052.ref026" ref-type="bibr">26</xref>–<xref rid="pcbi.1010052.ref028" ref-type="bibr">28</xref>]? For HIV-1: how comparable are published anti-HIV-1 antibodies relative to anti-SARS-CoV-2 antibodies as well as to HIV-1 patient repertoires, and how common are public antibody sequences reported in [<xref rid="pcbi.1010052.ref007" ref-type="bibr">7</xref>]? For DENV: how common are the convergent antibodies reported in recent studies [<xref rid="pcbi.1010052.ref029" ref-type="bibr">29</xref>–<xref rid="pcbi.1010052.ref031" ref-type="bibr">31</xref>]? We show that AIRRscape provides an intuitive and explorable visualization of the convergent antibody responses that occur in patients infected with SARS-CoV-2 or DENV, as well as the idiosyncratic responses that are typical in HIV-1 due to high SHM.</p>
  </sec>
  <sec sec-type="materials|methods" id="sec002">
    <title>2. Material and methods</title>
    <sec id="sec003">
      <title>2.1 Datasets</title>
      <p>Recent efforts by the AIRR Community [<xref rid="pcbi.1010052.ref032" ref-type="bibr">32</xref>,<xref rid="pcbi.1010052.ref033" ref-type="bibr">33</xref>] have led to the organization and standardization of T-cell and B-cell repertoire analysis, enhancing the accessibility of BCR repertoire datasets. Here we utilize two AIRR-seq data repositories, iReceptor and Observed Antibody Space [<xref rid="pcbi.1010052.ref034" ref-type="bibr">34</xref>–<xref rid="pcbi.1010052.ref036" ref-type="bibr">36</xref>], to gather BCR repertoire datasets in response to three viral pathogens: SARS-CoV-2, HIV-1, and DENV, the causative agents of COVID-19, AIDS, and dengue, respectively. Datasets primarily come from studies examining patient bulk BCR repertoires [<xref rid="pcbi.1010052.ref007" ref-type="bibr">7</xref>,<xref rid="pcbi.1010052.ref023" ref-type="bibr">23</xref>,<xref rid="pcbi.1010052.ref026" ref-type="bibr">26</xref>,<xref rid="pcbi.1010052.ref029" ref-type="bibr">29</xref>,<xref rid="pcbi.1010052.ref030" ref-type="bibr">30</xref>,<xref rid="pcbi.1010052.ref037" ref-type="bibr">37</xref>–<xref rid="pcbi.1010052.ref041" ref-type="bibr">41</xref>]. We also examine repositories of known monoclonal antibodies collated from multiple antibody discovery studies: CoV-AbDab for COVID-19 [<xref rid="pcbi.1010052.ref042" ref-type="bibr">42</xref>], and for HIV/AIDS the IEDB and CATNAP databases [<xref rid="pcbi.1010052.ref043" ref-type="bibr">43</xref>,<xref rid="pcbi.1010052.ref044" ref-type="bibr">44</xref>] and a recent dataset by Yacoob et al. [<xref rid="pcbi.1010052.ref045" ref-type="bibr">45</xref>]. For dengue, we focus on a set of described plasmablast sequences from two patients [<xref rid="pcbi.1010052.ref029" ref-type="bibr">29</xref>,<xref rid="pcbi.1010052.ref031" ref-type="bibr">31</xref>]. All datasets are summarized in <xref rid="pcbi.1010052.t002" ref-type="table">Table 2</xref>.</p>
      <table-wrap position="float" id="pcbi.1010052.t002">
        <object-id pub-id-type="doi">10.1371/journal.pcbi.1010052.t002</object-id>
        <label>Table 2</label>
        <caption>
          <title>Datasets used in AIRRscape.</title>
          <p>Datasets in italics are collections of antibodies.</p>
        </caption>
        <alternatives>
          <graphic xlink:href="pcbi.1010052.t002" id="pcbi.1010052.t002g" position="float"/>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="center" rowspan="1" colspan="1">Dataset</th>
                <th align="center" rowspan="1" colspan="1">Data type</th>
                <th align="center" rowspan="1" colspan="1">Sample</th>
                <th align="center" rowspan="1" colspan="1">Reference</th>
                <th align="center" rowspan="1" colspan="1">Source</th>
                <th align="center" rowspan="1" colspan="1">Number of sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">
                  <bold>COVID-19</bold>
                </td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">
                  <italic toggle="yes">SARS-CoV-2 mAbs</italic>
                </td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">
                  <italic toggle="yes">-</italic>
                </td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">2</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">CoV-AbDab database (2)</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1"><italic toggle="yes">4</italic>,<italic toggle="yes">306</italic></td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">
                  <bold>COVID-19</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">patient bulk repertoire</td>
                <td align="center" rowspan="1" colspan="1">p11</td>
                <td align="center" rowspan="1" colspan="1">23</td>
                <td align="center" rowspan="1" colspan="1">iReceptor (34)</td>
                <td align="center" rowspan="1" colspan="1">9,385</td>
              </tr>
              <tr>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">
                  <bold>COVID-19</bold>
                </td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">patient bulk repertoire</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">7450</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">38</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">iReceptor</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">15,645</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">
                  <bold>COVID-19</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">patient bulk repertoire</td>
                <td align="center" rowspan="1" colspan="1">galson-01</td>
                <td align="center" rowspan="1" colspan="1">26</td>
                <td align="center" rowspan="1" colspan="1">iReceptor</td>
                <td align="center" rowspan="1" colspan="1">29,795</td>
              </tr>
              <tr>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">
                  <bold>COVID-19</bold>
                </td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">patient bulk repertoire</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">M5</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">37</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">iReceptor</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">18,711</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">
                  <bold>Dengue</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">
                  <italic toggle="yes">dengue mAbs</italic>
                </td>
                <td align="center" rowspan="1" colspan="1">-</td>
                <td align="center" rowspan="1" colspan="1">31</td>
                <td align="center" rowspan="1" colspan="1">(31)</td>
                <td align="center" rowspan="1" colspan="1">
                  <italic toggle="yes">79</italic>
                </td>
              </tr>
              <tr>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">
                  <bold>Dengue</bold>
                </td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">patient bulk repertoire</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">d13</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">29</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">SRA</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">32,495</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">
                  <bold>Dengue</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">patient bulk repertoires</td>
                <td align="center" rowspan="1" colspan="1">45 patients</td>
                <td align="center" rowspan="1" colspan="1">30</td>
                <td align="center" rowspan="1" colspan="1">Observed Antibody Space (35)</td>
                <td align="center" rowspan="1" colspan="1">198,119</td>
              </tr>
              <tr>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">
                  <bold>Healthy control</bold>
                </td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">bulk repertoire</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">BX</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">40</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">SRA</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">50,942</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">
                  <bold>HIV-1</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">
                  <italic toggle="yes">HIV-1 mAbs</italic>
                </td>
                <td align="center" rowspan="1" colspan="1">-</td>
                <td align="center" rowspan="1" colspan="1">43</td>
                <td align="center" rowspan="1" colspan="1">IEDB (43)</td>
                <td align="center" rowspan="1" colspan="1">
                  <italic toggle="yes">98</italic>
                </td>
              </tr>
              <tr>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">
                  <bold>HIV-1</bold>
                </td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">
                  <italic toggle="yes">HIV-1 mAbs</italic>
                </td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">-</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">44</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">CATNAP (44)</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">
                  <italic toggle="yes">441</italic>
                </td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">
                  <bold>HIV-1</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">
                  <italic toggle="yes">HIV-1 mAbs</italic>
                </td>
                <td align="center" rowspan="1" colspan="1">-</td>
                <td align="center" rowspan="1" colspan="1">45</td>
                <td align="center" rowspan="1" colspan="1">(45)</td>
                <td align="center" rowspan="1" colspan="1">
                  <italic toggle="yes">83</italic>
                </td>
              </tr>
              <tr>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">
                  <bold>HIV-1</bold>
                </td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">patient bulk repertoire</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">NIH45</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">41</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">iReceptor</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">14,644</td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">
                  <bold>HIV-1</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">patient bulk repertoire</td>
                <td align="center" rowspan="1" colspan="1">MT1214</td>
                <td align="center" rowspan="1" colspan="1">39</td>
                <td align="center" rowspan="1" colspan="1">iReceptor</td>
                <td align="center" rowspan="1" colspan="1">33,855</td>
              </tr>
              <tr>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">
                  <bold>HIV-1</bold>
                </td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">patient bulk repertoires</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">6 CAPRISA patients</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">7</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">Observed Antibody Space</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">184,294</td>
              </tr>
            </tbody>
          </table>
        </alternatives>
      </table-wrap>
    </sec>
    <sec id="sec004">
      <title>2.2 Data processing</title>
      <p>BCR repertoire datasets are first downloaded either as tab-delimited files that follow AIRR Community standards or as sequence files that are partially processed, e.g. using the pRESTO module of the Immcantation suite [<xref rid="pcbi.1010052.ref046" ref-type="bibr">46</xref>]. For the repertoires in the latter category, the processing is completed using two Dockerized Change-O scripts from the Immcantation suite, ‘changeo-igblast’ and ‘changeo-clone’ [<xref rid="pcbi.1010052.ref047" ref-type="bibr">47</xref>]. The collated lists of antibodies against SARS-CoV-2 and HIV-1 (from the IEDB database only) are focused on protein sequence and do not include SHM, the % nucleotide divergence from germline V-gene, which thus needs to be calculated separately. For those antibody sequences we first run a tblastn search of the NCBI nr/nt database to find perfectly matched nucleotide sequences, and then use the Change-O scripts for processing (after checking to ensure the source is the same antibody without codon optimization). We subsequently color the SHM values of these sequences to highlight this additional step. The resulting repertoire datasets now follow the AIRR Community standards, with columns indicating the assigned V-gene (<italic toggle="yes">v_call</italic>), assigned J-gene (<italic toggle="yes">j_call</italic>), mutation from germline V-gene (<italic toggle="yes">v_identity</italic>), and assigned V(D)J junction amino acid sequence (<italic toggle="yes">junction_aa</italic>).</p>
      <p>A custom R function is used to further process the BCR repertoire datasets before visualization with Shiny. First we calculate the level of SHM from germline V-gene using the standard column <italic toggle="yes">v_identity</italic>. We also calculate CDR3 amino acid length as defined by the international ImMunoGeneTics information system (IMGT) by removing the first and last residue in the standard column <italic toggle="yes">junction_aa</italic>, with the new value called <italic toggle="yes">cdr3length_imgt</italic>. All sequences with stop codons and sequences with CDR3 lengths that are missing, not divisible by 3, or fewer than 3 amino acids are then removed. Lastly, we create additional columns used in our tool, namely v<italic toggle="yes">gf</italic> for the assigned V-gene family, <italic toggle="yes">vgf_jgene</italic> for the V-gene family + J-gene assignment, <italic toggle="yes">ncount</italic> for the count of sequences per unique combination of v<italic toggle="yes">gf_jgene</italic> + <italic toggle="yes">cdr3length_imgt</italic>, and <italic toggle="yes">shm_mean</italic> and <italic toggle="yes">shm_max</italic> for mean or maximum SHM from its germline V-gene, respectively, per unique combination of v<italic toggle="yes">gf_jgene + cdr3length_imgt</italic>. This function (AIRRscapeprocess) is embedded in the <italic toggle="yes">Import Data</italic> tab of the AIRRscape tool to allow researchers to modify and combine user-supplied datasets.</p>
      <p>To visualize multiple repertoires simultaneously, sets of antibodies and/or repertoires are combined in two possible configurations. The first option visualizes a set as separate faceted panels for individual repertoires (see 2.3). The second option combines these repertoires into a single panel, to enable searches of antibody convergence. Due to their broader importance, only heavy chain antibody sequences are visualized in each of these combined repertoires [<xref rid="pcbi.1010052.ref048" ref-type="bibr">48</xref>,<xref rid="pcbi.1010052.ref049" ref-type="bibr">49</xref>]. For all of the repertoire-based visualizations, we compact the individual repertoires by collapsing all sequences with the same v<italic toggle="yes">gf_jgene</italic> + <italic toggle="yes">cdr3length_imgt</italic> bin assignments and identical CDR3 amino acid motifs. In datasets containing multiple individuals, we compact only individual repertoires before combining them. A depiction of the workflow of dataset processing is summarized in <xref rid="pcbi.1010052.g001" ref-type="fig">Fig 1</xref>.</p>
      <fig position="float" id="pcbi.1010052.g001">
        <object-id pub-id-type="doi">10.1371/journal.pcbi.1010052.g001</object-id>
        <label>Fig 1</label>
        <caption>
          <title>Workflow of repertoire data retrieval and processing.</title>
        </caption>
        <graphic xlink:href="pcbi.1010052.g001" position="float"/>
      </fig>
    </sec>
    <sec id="sec005">
      <title>2.3 AIRRscape application</title>
      <p>AIRRscape is developed as an interactive web application using R Shiny. We use AIRRscape to visualize the main features of BCR repertoire datasets from processed tab-delimited files. To begin, in the <italic toggle="yes">Import Data</italic> tab researchers have the option to import, convert and combine up to six separate BCR repertoires following AIRR Community standards (as .tsv or .tab files, no metadata required), which are downloaded in the two configurations after combining (see 2.2). Next, in the <italic toggle="yes">AIRRscape</italic> tab researchers can explore the user-supplied or pre-loaded datasets as a generated heatmap with either multiple panels of individual BCR repertoires (<xref rid="pcbi.1010052.g002" ref-type="fig">Fig 2A</xref>) or a single panel combining multiple repertoires (<xref rid="pcbi.1010052.g002" ref-type="fig">Fig 2B</xref>). The x-axis of the heatmap shows antibodies binned according to their assigned V-gene family + J-gene germline, while the y-axis shows CDR3 length. Left of the <italic toggle="yes">Import Data</italic> and <italic toggle="yes">AIRRscape</italic> tabs, the user can choose datasets to visualize one of three parameters for coloring the bins: 1) by percent of overall total antibody sequences, 2) by average SHM of the bin, or 3) by maximum SHM of the bin. The user can then hover over the paneled heatmaps to view an interactive popup displaying a bin’s attributes (<xref rid="pcbi.1010052.g002" ref-type="fig">Fig 2B</xref>). Clicking on a single bin or selecting multiple bins using a drawn rectangle produces a table of antibodies and their features (<xref rid="pcbi.1010052.g003" ref-type="fig">Fig 3</xref>). Within the table, users can query by or focus on any of the antibody features loaded in the datasets. Selected antibodies can be downloaded or further explored via their topologies (i.e. their phylogenetic relationship, with the caveat that convergent antibodies are not clonally related).</p>
      <fig position="float" id="pcbi.1010052.g002">
        <object-id pub-id-type="doi">10.1371/journal.pcbi.1010052.g002</object-id>
        <label>Fig 2</label>
        <caption>
          <title>AIRRscape visualization of immune repertoires.</title>
          <p>Heatmaps comparing characteristics of (A) separate and (B) combined datasets for anti-SARS-CoV-2 and anti-HIV-1 antibodies.</p>
        </caption>
        <graphic xlink:href="pcbi.1010052.g002" position="float"/>
      </fig>
      <fig position="float" id="pcbi.1010052.g003">
        <object-id pub-id-type="doi">10.1371/journal.pcbi.1010052.g003</object-id>
        <label>Fig 3</label>
        <caption>
          <title>AIRRscape interface showing antibodies and CDR3 amino acid topology of selected antibody bin.</title>
          <p>Selected bin is highlighted in the red box of <xref rid="pcbi.1010052.g002" ref-type="fig">Fig 2B</xref>. SHM values in blue are calculated after an additional tblastn search of the NCBI nr/nt database.</p>
        </caption>
        <graphic xlink:href="pcbi.1010052.g003" position="float"/>
      </fig>
      <p>Below the table of selected antibodies, AIRRscape displays interactive topologies of CDR3 amino acid sequence similarity (<xref rid="pcbi.1010052.g003" ref-type="fig">Fig 3</xref>). Binning antibodies both by germline assignment as well as CDR3 length enables examination of these CDR3 motifs in a phylogenetic framework, since the CDR3 motifs will be ‘aligned’ when constrained to bins with a given CDR3 length. The labels of the topology tips conveniently display antibody names, assigned V-genes, and CDR3 amino acid sequences. The major advantage of this approach is that thousands of antibody CDR3 sequences can be visualized via a web browser for quick and easy exploration by researchers without command-line expertise.</p>
      <p>AIRRscape allows for multiple options to create CDR3 topologies. First, a user may select a set of antibodies from the table for constructing their topology via either the neighbor-joining or parsimony tree building methods using the Phangorn package [<xref rid="pcbi.1010052.ref050" ref-type="bibr">50</xref>,<xref rid="pcbi.1010052.ref051" ref-type="bibr">51</xref>]. Alternatively, a user can select a single antibody sequence of interest to identify all similar sequences in that bin within a chosen amino acid identity threshold. AIRRscape will then display a parsimony topology of these nearest sequences. The options for identity threshold are 50%, 70% used in [<xref rid="pcbi.1010052.ref007" ref-type="bibr">7</xref>], 80% used in [<xref rid="pcbi.1010052.ref006" ref-type="bibr">6</xref>], and 100% used in [<xref rid="pcbi.1010052.ref001" ref-type="bibr">1</xref>]. Topology tip colors are unique to each dataset. Lastly, the user has the ability to change both the height and width of the topology. Height adjustment allows the user to more easily visualize a small topology or examine a large topology (up to 500 sequences) across more than one visible page; adjusting the width allows the user to see the full tip label when there are long branch lengths.</p>
      <p>Two custom R scripts, <italic toggle="yes">airrscape_preprocessing</italic>.<italic toggle="yes">R</italic> and <italic toggle="yes">airrscape_processing</italic>.<italic toggle="yes">R</italic>, are included to document the data processing and to manually convert files that follow the aforementioned AIRR Community standards for loading into AIRRscape. Both the pre-processing scripts and the R Shiny code for AIRRscape are available on GitHub at <ext-link xlink:href="https://github.com/czbiohub/AIRRscape" ext-link-type="uri">https://github.com/czbiohub/AIRRscape</ext-link>. AIRRscape can be run locally using RStudio within a browser, or it can be used on the web at <ext-link xlink:href="https://airrscape.czbiohub.org/" ext-link-type="uri">https://airrscape.czbiohub.org</ext-link>.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="sec006">
    <title>3. Results</title>
    <p>To illustrate the utility of AIRRscape, we used it to explore the adaptive BCR responses to three viral pathogens: SARS-CoV-2, HIV-1 and DENV.</p>
    <sec id="sec007">
      <title>3.1 anti-SARS-CoV-2 antibody datasets share characteristics and convergent motifs</title>
      <p>We first examined the CoV-AbDab database of validated monoclonal anti-SARS-CoV-2 antibodies and compared them to published bulk BCR repertoires of four COVID-19 patients, as well as to a healthy control bulk BCR repertoire. We visualized 2,153 paired antibody sequences from the CoV-AbDab dataset and a single representative repertoire from each study of COVID-19 patient bulk repertoires ([<xref rid="pcbi.1010052.ref023" ref-type="bibr">23</xref>,<xref rid="pcbi.1010052.ref026" ref-type="bibr">26</xref>,<xref rid="pcbi.1010052.ref037" ref-type="bibr">37</xref>,<xref rid="pcbi.1010052.ref038" ref-type="bibr">38</xref>], <xref rid="pcbi.1010052.t002" ref-type="table">Table 2</xref>). After removing duplicate sequences (as described in 2.2), we compared 73,536 COVID-19 patient antibody CDRH3 sequences and 50,942 healthy control sequences (<xref rid="pcbi.1010052.g004" ref-type="fig">Fig 4</xref>).</p>
      <fig position="float" id="pcbi.1010052.g004">
        <object-id pub-id-type="doi">10.1371/journal.pcbi.1010052.g004</object-id>
        <label>Fig 4</label>
        <caption>
          <title>AIRRscape heatmaps comparing anti-SARS-CoV-2 antibodies, bulk BCR repertoires of four COVID-19 patients, and a healthy control bulk BCR repertoire.</title>
        </caption>
        <graphic xlink:href="pcbi.1010052.g004" position="float"/>
      </fig>
      <p>We first asked how representative the anti-SARS-CoV-2 antibodies are relative to patient repertoires and relative to a healthy control repertoire, based on the heatmap visualizations in AIRRscape. This visual analysis suggested that the overall pattern of heavy chain V-gene family + J-gene pairings versus CDRH3 length distribution appears similar among the CoV-AbDab dataset, the four patient repertoires, and the healthy control repertoire (<xref rid="pcbi.1010052.g004" ref-type="fig">Fig 4</xref>). The most common V+J gene family assignments in all datasets were IGHV3+IGHJ4, IGHV3+IGHJ6, IGHV4+IGHJ4, IGHV4+IGHJ6, IGHV1+IGHJ4 and IGHV1+IGHJ6. A notable visual difference between the datasets was the presence or absence of sequences assigned to IGHV7 (<xref rid="pcbi.1010052.g004" ref-type="fig">Fig 4</xref>), which is not unexpected given that this gene ‘family’ consists of a single functional V-gene that does not occur in all individuals [<xref rid="pcbi.1010052.ref001" ref-type="bibr">1</xref>]. SHM levels among the anti-SARS-CoV-2 antibodies (mean 2.3%) were lower than the four patient repertoires (overall mean 3.7%) and the healthy control repertoire (mean 3.3%), although the patient from the Galson et al. study had noticeably higher SHM levels (mean 5.5%). These data suggest that a majority of neutralizing antibodies against SARS-CoV-2 do not diverge greatly from germline and therefore may be more easily elicited among patients.</p>
      <p>Next we used AIRRscape to visualize convergent clonotypes among anti-SARS-CoV-2 antibodies and COVID-19 patient bulk BCR repertoires. Visualizations were created based on their v<italic toggle="yes">gf_jgene</italic> + <italic toggle="yes">cdr3length_imgt</italic> bin assignments, where a bin <italic toggle="yes">x_y_z</italic> represents IGHV<italic toggle="yes">x</italic> germline assignment + IGHJ<italic toggle="yes">y</italic> germline assignment + CDR3 length of <italic toggle="yes">z</italic> aa. As use cases, we focused on three recently reported convergences, visualized as four bins: both <italic toggle="yes">3_4_11</italic> and <italic toggle="yes">3_6_11</italic> for an IGHV3-53-based cluster as reported by Yuan et al. [<xref rid="pcbi.1010052.ref028" ref-type="bibr">28</xref>] and Galson et al. [<xref rid="pcbi.1010052.ref026" ref-type="bibr">26</xref>]; <italic toggle="yes">3_6_14</italic> for a large cluster found by Galson et al. [<xref rid="pcbi.1010052.ref026" ref-type="bibr">26</xref>]; and <italic toggle="yes">1_3_16</italic> for a cluster reported by Robbiani et al. [<xref rid="pcbi.1010052.ref027" ref-type="bibr">27</xref>]. Within each bin, we selected one published monoclonal antibody and examined the topology of similar CDRH3 motifs among all the COVID-19 datasets, using the 80% aa sequence identity threshold selected by Soto et al. [<xref rid="pcbi.1010052.ref006" ref-type="bibr">6</xref>]. As expected, convergence across all four bins was observed (<xref rid="pcbi.1010052.g005" ref-type="fig">Fig 5</xref> and Figs A-C in <xref rid="pcbi.1010052.s001" ref-type="supplementary-material">S1 Data</xref>), with each containing 12–30 CDRH3 motifs from the CoV-AbDab dataset; these motifs were found across seven or more unique studies. Three of the bins show convergent motifs among multiple patient repertoires (<xref rid="pcbi.1010052.g005" ref-type="fig">Fig 5</xref> and Figs A and C in <xref rid="pcbi.1010052.s001" ref-type="supplementary-material">S1 Data</xref>), with two also showing convergence among three of the four patient repertoires. Furthermore, two of the bins show convergence to the healthy control repertoire (<xref rid="pcbi.1010052.g005" ref-type="fig">Fig 5</xref> and Fig A in <xref rid="pcbi.1010052.s001" ref-type="supplementary-material">S1 Data</xref>). The three convergent motifs seen in multiple COVID-19 patient repertoires were also found in HIV-1 and dengue patient repertoires (see 3.4). While SHM is not included in the CDRH3 topologies, examination of the convergent sequences indicated that they all show low SHM (0–4%).</p>
      <fig position="float" id="pcbi.1010052.g005">
        <object-id pub-id-type="doi">10.1371/journal.pcbi.1010052.g005</object-id>
        <label>Fig 5</label>
        <caption>
          <title>SARS-CoV-2 convergent clonotypes to mAb DH1149 in the 3_6_14 bin.</title>
          <p>An 80% identity threshold is used to calculate convergence. Tips are colored by dataset source. Purple tips are published anti-COVID-19 antibodies from 7 different studies, dark gray tips are antibody sequences from a healthy donor BCR repertoire, and orange through brown shaded tips are antibody sequences from COVID-19 patient BCR repertoires.</p>
        </caption>
        <graphic xlink:href="pcbi.1010052.g005" position="float"/>
      </fig>
    </sec>
    <sec id="sec008">
      <title>3.2 anti-HIV-1 antibody datasets display idiosyncrasies</title>
      <p>We collated anti-HIV-1 monoclonal antibodies from two databases and one study [<xref rid="pcbi.1010052.ref043" ref-type="bibr">43</xref>–<xref rid="pcbi.1010052.ref045" ref-type="bibr">45</xref>], and compared this set to published bulk BCR repertoires of eight HIV-1 patients. From the databases we visualized 358 sequences. For the HIV-1 patient bulk BCR repertoires, 33,855 antibody sequences from patient MT1214 [<xref rid="pcbi.1010052.ref039" ref-type="bibr">39</xref>], 14,644 from patient NIH45 [<xref rid="pcbi.1010052.ref041" ref-type="bibr">41</xref>], and 184,294 from six CAPRISA patients [<xref rid="pcbi.1010052.ref007" ref-type="bibr">7</xref>] were visualized after removing duplicate sequences (see 2.2; Fig D in <xref rid="pcbi.1010052.s001" ref-type="supplementary-material">S1 Data</xref>). Although patient NIH45 was only sequenced for IGHV1 genes, this partial ‘repertoire’ was included because it is the original source of the broadly neutralizing antibody VRC01 [<xref rid="pcbi.1010052.ref041" ref-type="bibr">41</xref>].</p>
      <p>The heatmap visualizations in AIRRscape were used to compare published anti-HIV-1 antibodies to anti-SARS-CoV-2 antibodies and to two HIV-1 patient repertoires. While the number of anti-HIV-1 antibodies was sparse relative to that of anti-SARS-CoV-2 antibodies, they appeared to have similar heavy chain V-gene family + J-gene pairings (<xref rid="pcbi.1010052.g002" ref-type="fig">Fig 2A</xref>). There were noticeable differences in both SHM and CDRH3 length, consistent with previous anti-HIV-1 antibody repertoire characterizations [<xref rid="pcbi.1010052.ref052" ref-type="bibr">52</xref>,<xref rid="pcbi.1010052.ref053" ref-type="bibr">53</xref>]. The anti-HIV-1 antibody dataset showed higher SHM (mean 12.6% vs. 2.3%, <xref rid="pcbi.1010052.g002" ref-type="fig">Fig 2A</xref>) and longer CDRH3 lengths (20.4 vs. 15.8 aa) than the CoV-AbDab dataset. Comparing published anti-HIV-1 antibodies with the HIV-1 patient repertoires also revealed higher SHM (mean 12.6% vs. 5.0%) and longer CDRH3 lengths (mean 20.4 vs. 16.0 aa), which contrasts with the COVID-19 results in 3.1 (Fig D in <xref rid="pcbi.1010052.s001" ref-type="supplementary-material">S1 Data</xref>) and indicates strong diversifying selection away from unmutated, naive antibodies.</p>
      <p>We used AIRRscape to visualize convergent clonotypes among anti-HIV-1 antibodies and HIV-1 patient bulk BCR repertoires, focusing on ten recently reported convergences from Setliff et al. [<xref rid="pcbi.1010052.ref007" ref-type="bibr">7</xref>], visualized as eight bins, as well as the inferred VRC01 germline CDR3 motif [<xref rid="pcbi.1010052.ref041" ref-type="bibr">41</xref>]. As per 3.1, we selected one published monoclonal antibody within each bin and examined the topology of similar CDRH3 motifs among all the HIV-1 datasets, this time using a lower 70% aa sequence identity threshold and requiring identical V-gene assignment, following Setliff et al. [<xref rid="pcbi.1010052.ref007" ref-type="bibr">7</xref>]. Four of the bins showed limited convergence among HIV-1 datasets (<xref rid="pcbi.1010052.g006" ref-type="fig">Fig 6</xref> and Fig E in <xref rid="pcbi.1010052.s001" ref-type="supplementary-material">S1 Data</xref>), with motifs shared among two, three, or four patient repertoires. Despite including two antibody datasets from studies on the VRC01 antibody lineage, we notably could not find any convergence to the VRC01 germline CDR3 motif among the HIV-1 datasets. The complex evolution from germline and mutational requirements of neutralizing HIV-1 antibodies are consistent with the rarity of success in naturally achieving humoral neutralization in infected individuals and with challenges encountered in vaccine development.</p>
      <fig position="float" id="pcbi.1010052.g006">
        <object-id pub-id-type="doi">10.1371/journal.pcbi.1010052.g006</object-id>
        <label>Fig 6</label>
        <caption>
          <title>HIV-1 convergent clonotypes to antibodies from Setliff et al. (2018; Fig 4).</title>
          <p>(A) Convergent clonotypes to mAb 02-o in the 1_4_13 bin. (B) Convergent clonotypes to mAb 02-s in the 1_4_14 bin. (C) Convergent clonotypes to mAb HK20 in the 1_3_15 bin. A 70% identity threshold is used to calculate convergence. Tips are colored by dataset source. Purple tips are published anti-COVID-19 antibodies, and green shaded tips are antibody sequences from HIV-1 patient BCR repertoires.</p>
        </caption>
        <graphic xlink:href="pcbi.1010052.g006" position="float"/>
      </fig>
    </sec>
    <sec id="sec009">
      <title>3.3 anti-dengue antibody datasets share convergent motifs</title>
      <p>AIRRscape was used to visualize both reported and potentially undiscovered convergence among the collated dengue datasets. We searched for convergence between 38 unique antibody sequences from plasmablasts isolated from two Colombian dengue patients and bulk BCR repertoires of dengue patients from Colombian and Nicaraguan cohorts. Patient bulk BCR repertoires consist of one Colombian patient (d13; [<xref rid="pcbi.1010052.ref029" ref-type="bibr">29</xref>]) and a collection of 45 Nicaraguan patient repertoires [<xref rid="pcbi.1010052.ref030" ref-type="bibr">30</xref>]. After removing duplicates, we compared 32,495 antibody sequences from Patient d13 and 198,119 from the Nicaraguan cohort (Fig F in <xref rid="pcbi.1010052.s001" ref-type="supplementary-material">S1 Data</xref>).</p>
      <p>Evidence of convergent antibody motifs was previously found in independent studies of the Colombian (n = 2) and Nicaraguan (n = 45) patients. Plasmablast sequences in the Colombian patients were reported to cluster into 15 clonal families, with one clonal family (CF1) found in both patients [<xref rid="pcbi.1010052.ref031" ref-type="bibr">31</xref>]. Similarly, analysis of the Nicaraguan cohort found six CDRH3 motifs common to multiple patients [<xref rid="pcbi.1010052.ref030" ref-type="bibr">30</xref>].</p>
      <p>In our analysis, we began with each of the 15 plasmablast clonal families, and searched for similar CDRH3 motifs among the full dengue dataset, using the 80% aa sequence identity threshold as per Soto et al. [<xref rid="pcbi.1010052.ref006" ref-type="bibr">6</xref>]. Five of the 15 clonal families showed convergence across both Colombian and Nicaraguan cohorts (<xref rid="pcbi.1010052.t003" ref-type="table">Table 3</xref> and <xref rid="pcbi.1010052.g007" ref-type="fig">Fig 7</xref> and Figs G-I in <xref rid="pcbi.1010052.s001" ref-type="supplementary-material">S1 Data</xref>). Of these five, we identified CF1 from the Colombian cohort as the most prevalent clonal family in the Nicaraguan dataset, occurring in 16 donors (<xref rid="pcbi.1010052.t003" ref-type="table">Table 3</xref> and <xref rid="pcbi.1010052.g007" ref-type="fig">Fig 7</xref>). We also found a previously unreported instance of convergence in the Colombian dataset. CDRH3 motifs from the CF6 clonal family identified in patient d20 were also found in the patient d13 bulk BCR repertoire, as well as in two patient repertoires from the Nicaraguan bulk dataset (<xref rid="pcbi.1010052.t003" ref-type="table">Table 3</xref> and Fig G in <xref rid="pcbi.1010052.s001" ref-type="supplementary-material">S1 Data</xref>).</p>
      <fig position="float" id="pcbi.1010052.g007">
        <object-id pub-id-type="doi">10.1371/journal.pcbi.1010052.g007</object-id>
        <label>Fig 7</label>
        <caption>
          <title>Dengue convergent clonotypes to CF1 (Zanini et al. 2018).</title>
          <p>An 80% identity threshold is used to calculate convergence. Tips are colored by dataset source. Purple tips are plasmablast sequences reported by Zanini et al. (2018) isolated from two Colombian patients (d13 and d20), blue tips are antibody sequences from the BCR repertoire of patient d13, and gold tips are antibody sequences from a cohort of Nicaraguan patient BCR repertoires.</p>
        </caption>
        <graphic xlink:href="pcbi.1010052.g007" position="float"/>
      </fig>
      <table-wrap position="float" id="pcbi.1010052.t003">
        <object-id pub-id-type="doi">10.1371/journal.pcbi.1010052.t003</object-id>
        <label>Table 3</label>
        <caption>
          <title>Dengue convergence to plasmablast clonal families.</title>
        </caption>
        <alternatives>
          <graphic xlink:href="pcbi.1010052.t003" id="pcbi.1010052.t003g" position="float"/>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
              <col align="left" valign="middle" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="center" rowspan="1" colspan="1">Clonal family</th>
                <th align="center" rowspan="1" colspan="1">V_J_CDR3 length</th>
                <th align="center" rowspan="1" colspan="1">Plasmablast donor</th>
                <th align="center" rowspan="1" colspan="1">Colombian p13 Bulk matches?</th>
                <th align="center" rowspan="1" colspan="1">Nicaraguan cohort matches?</th>
                <th align="center" rowspan="1" colspan="1">Nicaraguan sequence matches</th>
                <th align="center" rowspan="1" colspan="1">Nicaraguan donors with match</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">
                  <bold>CF1</bold>
                </td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">4_5_10</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">p13, p20</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">yes</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">yes</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">41</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">
                  <bold>16</bold>
                </td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">
                  <bold>CF2</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">1_4_15</td>
                <td align="center" rowspan="1" colspan="1">p13</td>
                <td align="center" rowspan="1" colspan="1">yes</td>
                <td align="center" rowspan="1" colspan="1">no</td>
                <td align="center" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">
                  <bold>CF3</bold>
                </td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">1_5_16</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">p13</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">yes</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">no</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1"/>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">
                  <bold>CF4</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">1_4_16</td>
                <td align="center" rowspan="1" colspan="1">p20</td>
                <td align="center" rowspan="1" colspan="1">no</td>
                <td align="center" rowspan="1" colspan="1">no</td>
                <td align="center" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">
                  <bold>CF5</bold>
                </td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">1_3_17</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">p13</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">yes</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">no</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1"/>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">
                  <bold>CF6</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">1_4_13</td>
                <td align="center" rowspan="1" colspan="1">p20</td>
                <td align="center" rowspan="1" colspan="1">
                  <bold>yes</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">yes</td>
                <td align="center" rowspan="1" colspan="1">2</td>
                <td align="center" rowspan="1" colspan="1">
                  <bold>2</bold>
                </td>
              </tr>
              <tr>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">
                  <bold>CF7</bold>
                </td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">1_5_16</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">p13</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">yes</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">yes</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">24</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">
                  <bold>5</bold>
                </td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">
                  <bold>CF8</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">1_5_17</td>
                <td align="center" rowspan="1" colspan="1">p13</td>
                <td align="center" rowspan="1" colspan="1">yes</td>
                <td align="center" rowspan="1" colspan="1">yes</td>
                <td align="center" rowspan="1" colspan="1">1</td>
                <td align="center" rowspan="1" colspan="1">
                  <bold>1</bold>
                </td>
              </tr>
              <tr>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">
                  <bold>CF9</bold>
                </td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">1_5_20</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">p13</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">yes</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">yes</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">7</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">
                  <bold>3</bold>
                </td>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">
                  <bold>CF10</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">3_5_14</td>
                <td align="center" rowspan="1" colspan="1">p13</td>
                <td align="center" rowspan="1" colspan="1">yes</td>
                <td align="center" rowspan="1" colspan="1">no</td>
                <td align="center" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">
                  <bold>CF11</bold>
                </td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">3_6_23</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">p13</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">yes</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">no</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1"/>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">
                  <bold>CF12</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">3_4_17</td>
                <td align="center" rowspan="1" colspan="1">p20</td>
                <td align="center" rowspan="1" colspan="1">no</td>
                <td align="center" rowspan="1" colspan="1">no</td>
                <td align="center" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">
                  <bold>CF13</bold>
                </td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">4_5_18</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">p13</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">yes</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">no</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1"/>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="center" rowspan="1" colspan="1">
                  <bold>CF14</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">4_4_15</td>
                <td align="center" rowspan="1" colspan="1">p20</td>
                <td align="center" rowspan="1" colspan="1">no</td>
                <td align="center" rowspan="1" colspan="1">no</td>
                <td align="center" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">
                  <bold>CF15</bold>
                </td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">4_5_23</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">p13</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">yes</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1">no</td>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1"/>
                <td align="center" style="background-color:#E7E7E7" rowspan="1" colspan="1"/>
              </tr>
            </tbody>
          </table>
        </alternatives>
      </table-wrap>
      <p>The six common CDRH3 motifs reported in the Nicaraguan dengue patients were also explored using AIRRscape. These six motifs group into two clusters by amino acid similarity. We found that the first cluster is common among the Nicaraguan dengue cohort, occurring in 17 patients, but not seen in the Colombian dataset. Notably, we found that the second cluster was convergent with the CF1 clonal family ([<xref rid="pcbi.1010052.ref031" ref-type="bibr">31</xref>]; Fig I in <xref rid="pcbi.1010052.s001" ref-type="supplementary-material">S1 Data</xref>), demonstrating its frequent occurrence. These data demonstrate how repertoire convergence in populations can occur at different geographic levels, some more restricted than others. This could be due to regional differences or similarities in factors such as infection or vaccine history, genetics, and environment.</p>
    </sec>
    <sec id="sec010">
      <title>3.4 SARS-CoV-2, HIV-1, and DENV datasets share a limited set of motifs</title>
      <p>We examined the SARS-CoV-2, HIV-1, and DENV antibody datasets together, to detect whether the reported convergent motifs are also found across diverse patient repertoires. Among the anti-SARS-CoV-2 antibody datasets, three convergent motifs seen in multiple COVID-19 patient repertoires were also found in both HIV-1 and dengue patient repertoires (<xref rid="pcbi.1010052.g008" ref-type="fig">Fig 8</xref> and Figs J and K in <xref rid="pcbi.1010052.s001" ref-type="supplementary-material">S1 Data</xref>). The three convergent motifs, found in the 3_6_14, 3_4_11 and 3_6_11 bins, were found in 1, 3, and 2 HIV-1 patient repertoires and 6, 8, and 9 dengue patient repertoires, respectively. However, convergence with exact V-gene assignment was less common, found only in the two bins representing the IGHV3-53-based cluster (see 3.1; Figs J and K in <xref rid="pcbi.1010052.s001" ref-type="supplementary-material">S1 Data</xref>).</p>
      <fig position="float" id="pcbi.1010052.g008">
        <object-id pub-id-type="doi">10.1371/journal.pcbi.1010052.g008</object-id>
        <label>Fig 8</label>
        <caption>
          <title>SARS-CoV-2, HIV-1, &amp; dengue convergent clonotypes to anti-SARS-CoV-2 mAb DH1149 in the 3_6_14 bin.</title>
          <p>An 80% identity threshold is used to calculate convergence. Tips are colored by dataset source. Purple tips are published anti-COVID-19 antibodies from 7 different studies, dark gray tips are antibody sequences from a healthy donor BCR repertoire, and orange through brown shaded tips are antibody sequences from COVID-19 patient BCR repertoires. Green shaded tips are antibody sequences from HIV-1 patient BCR repertoires. Gold tips are antibody sequences from a cohort of Nicaraguan dengue patient BCR repertoires.</p>
        </caption>
        <graphic xlink:href="pcbi.1010052.g008" position="float"/>
      </fig>
      <p>Among the anti-HIV-1 and anti-dengue antibody datasets, convergence across other patient repertoires was less common. Of the reported HIV-1 convergent motifs, we found no convergence among COVID-19 patient repertoires and found only one motif with convergence in dengue patient repertoires (Fig L in <xref rid="pcbi.1010052.s001" ref-type="supplementary-material">S1 Data</xref>). Of the five clonal families showing convergence across dengue patient cohorts, we found no convergence among HIV-1 patient repertoires, and only one motif with convergence in a single COVID-19 patient repertoire (Fig M in <xref rid="pcbi.1010052.s001" ref-type="supplementary-material">S1 Data</xref>). These data suggest that public antibody motifs are rare but findable using AIRRscape. However, additional knowledge of disease history in such datasets is needed before drawing conclusions. For example, it is not known whether any of the patient repertoires with such convergence have multiple viral infections.</p>
    </sec>
  </sec>
  <sec sec-type="conclusions" id="sec011">
    <title>4. Discussion</title>
    <p>The importance of understanding BCR repertoires has gained increasing appreciation, especially as a result of the current COVID-19 pandemic. Along with rapidly advancing sequencing capabilities, this has led to the study and publication of dozens of individual BCR repertoires, particularly from patients infected by well-studied infectious pathogens as well as from healthy controls, e.g. [<xref rid="pcbi.1010052.ref001" ref-type="bibr">1</xref>,<xref rid="pcbi.1010052.ref006" ref-type="bibr">6</xref>,<xref rid="pcbi.1010052.ref023" ref-type="bibr">23</xref>,<xref rid="pcbi.1010052.ref026" ref-type="bibr">26</xref>,<xref rid="pcbi.1010052.ref027" ref-type="bibr">27</xref>,<xref rid="pcbi.1010052.ref037" ref-type="bibr">37</xref>,<xref rid="pcbi.1010052.ref041" ref-type="bibr">41</xref>]. As with other examples of ‘big data’, there are many challenges in managing these datasets. In response, the AIRR Community has made significant efforts to standardize and curate BCR repertoires [<xref rid="pcbi.1010052.ref032" ref-type="bibr">32</xref>–<xref rid="pcbi.1010052.ref034" ref-type="bibr">34</xref>]. However, visualization and comparative analysis of these repertoires remains a challenge. To begin to address this gap we developed AIRRscape, a tool that leverages AIRR Community standards to visualize multiple BCR repertoires quickly and simultaneously. AIRRscape provides a high-level view of large datasets that allows researchers to investigate differences in commonly used repertoire characteristics, such as V-gene usage, J-gene usage, CDR3 length, and somatic hypermutation.</p>
    <p>Recent studies have found measurable convergence between individual BCR repertoires, particularly among individuals infected with a common antigen [<xref rid="pcbi.1010052.ref002" ref-type="bibr">2</xref>]. Such convergence has great implications for understanding immune responses to antigens and informing vaccine design. Therefore, a major aim of AIRRscape is to visualize related antibody sequences, particularly from different repertoires, using the commonly accepted characteristics of convergence, V-gene assignment, J-gene assignment, and CDR3 motif. We use phylogenetic methods to more easily visualize and understand differences among the motifs, keeping in mind that the visualizations are topologies of CDR3 motifs and not necessarily phylogenetic trees indicating common ancestry, e.g. when multiple individual repertoires are compared. The characteristics used to find convergence are the same as those used to define clonotypes, or clonal clusters of antibodies within individuals. Given that no consensus on clonotype definitions has been reached, with debate largely centered around thresholds of sequence identity in the CDR3 motif, AIRRscape does not require a priori clustering of clonotypes and creates topologies based on CDR3 amino acid sequences while being agnostic with respect to thresholds.</p>
    <p>We validated the utility of AIRRscape by exploring datasets of both antibodies and patient bulk BCR repertoires for three viral pathogens: SARS-CoV-2, HIV-1, and DENV. Among the COVID-19 datasets, we first visually confirmed that the set of known anti-SARS-CoV-2 antibodies is broadly similar both to a healthy BCR repertoire and to a collection of COVID-19 patient repertoires, as measured by heavy chain V-gene family + J-gene usage, CDRH3 length distribution, and relatively low levels of SHM from germline. This is consistent with studies made in the first months of the COVID-19 pandemic that concluded that anti-SARS-CoV-2 antibodies could likely be induced by vaccines [<xref rid="pcbi.1010052.ref054" ref-type="bibr">54</xref>]. We then used AIRRscape to examine convergence among anti-SARS-CoV-2 antibodies and COVID-19 patient BCR repertoires as reported by multiple studies [<xref rid="pcbi.1010052.ref026" ref-type="bibr">26</xref>–<xref rid="pcbi.1010052.ref028" ref-type="bibr">28</xref>]. COVID-19 convergent motifs are indeed present in currently known anti-SARS-CoV-2 antibodies as well as in four COVID-19 patient bulk BCR repertoires. COVID-19 convergent motifs were also identified among repertoires of healthy controls and dengue patients, which would not be expected to contain antibodies against SARS-CoV-2, but could be explained by the relative proximity of the motifs to germline sequences and/or to infection with other coronaviruses. Convergence of neutralizing antibody sequences among multiple COVID-19 repertoires is a strong indicator of similarity in SARS-CoV-2 immune responses and suggests that vaccines eliciting these antibodies will be broadly effective [<xref rid="pcbi.1010052.ref027" ref-type="bibr">27</xref>,<xref rid="pcbi.1010052.ref055" ref-type="bibr">55</xref>]. The discovery that some of these COVID-19 convergent motifs are public (i.e. also identified in our dengue, HIV-1, and healthy control samples) suggests that there is a general pre-existing foundation in populations towards COVID-19 protection. While a primed immune repertoire bodes well for robust vaccine responses, laboratory experiments are needed to determine whether these sequences are functional against SARS-CoV-2. Repertoires of patients infected by different SARS-CoV-2 variants could be explored using AIRRscape to find potential convergence among these datasets. Such convergence would indicate antibody motifs with potential to neutralize the range of known SARS-CoV-2 variants, which could be prioritized for reverse vaccinology research or development.</p>
    <p>In contrast to the COVID-19 datasets, the HIV-1 datasets are mostly idiosyncratic but do show limited convergence. Using AIRRscape, we analyzed anti-HIV-1 antibodies and eight HIV-1 patient bulk BCR repertoires. The heatmaps show high SHM, a common feature of neutralizing antibodies against HIV-1. We found limited convergence among the HIV-1 datasets and no convergence to the VRC01 germline CDR3 motif [<xref rid="pcbi.1010052.ref041" ref-type="bibr">41</xref>], even using a more permissive CDR3 sequence identity threshold. While the limited convergence appears at odds with the reporting of VRC01-like antibodies in multiple HIV-1 patients [<xref rid="pcbi.1010052.ref007" ref-type="bibr">7</xref>,<xref rid="pcbi.1010052.ref056" ref-type="bibr">56</xref>], the VRC01 class varies in CDRH3 similarity and is instead defined by 20–35% SHM in the germline VH1-2 gene and a 5 aa CDRL3 length [<xref rid="pcbi.1010052.ref057" ref-type="bibr">57</xref>,<xref rid="pcbi.1010052.ref058" ref-type="bibr">58</xref>]. These idiosyncratic characteristics underscore the difficulty in vaccine development for HIV-1.</p>
    <p>Examination of dengue datasets revealed evidence of convergent antibody motifs among two patient cohorts from Colombia and Nicaragua. Visualizing 15 focal plasmablast clonal families in AIRRscape, we found five were common to both patient cohorts, often in multiple patients. The most common convergent lineage CF1, seen in both Parameswaran et al. [<xref rid="pcbi.1010052.ref030" ref-type="bibr">30</xref>] and Zanini et al. [<xref rid="pcbi.1010052.ref031" ref-type="bibr">31</xref>], was found not to be broadly neutralizing against all DENV serotypes [<xref rid="pcbi.1010052.ref029" ref-type="bibr">29</xref>]. However, the second most commonly found lineage, CF7, includes the mAb J9 that Durham et al. [<xref rid="pcbi.1010052.ref029" ref-type="bibr">29</xref>] found to be broadly neutralizing. That one of two tested convergent antibody lineages shows broad neutralization suggests further investigations of convergence may be beneficial for focusing antibody discovery and vaccine design. Broad neutralization could be particularly important for treating dengue, where antibody-enhanced disease is a problem.</p>
    <p>As AIRRscape is in active development, we note some limitations and also envision future enhancements. AIRRscape is primarily an exploratory tool focused on visualization but various metrics could be used to formally measure overlap between repertoires [<xref rid="pcbi.1010052.ref017" ref-type="bibr">17</xref>,<xref rid="pcbi.1010052.ref059" ref-type="bibr">59</xref>]. AIRRscape does not visualize all of the sequences in the bulk BCR repertoire datasets; due to size and computing limitations in the Shiny application, large datasets are collapsed when V-gene + J-gene assignments as well as CDR3 amino acid motifs are identical. Similarly, to facilitate construction of topologies of CDR3 amino acid motifs we focus on those with exact same lengths, although it has been shown that functionally similar antibodies may have different CDR3 lengths [<xref rid="pcbi.1010052.ref060" ref-type="bibr">60</xref>,<xref rid="pcbi.1010052.ref061" ref-type="bibr">61</xref>]. While the variability of CDR3 is typically crucial for defining antigen specificity [<xref rid="pcbi.1010052.ref049" ref-type="bibr">49</xref>,<xref rid="pcbi.1010052.ref062" ref-type="bibr">62</xref>], other CDRs can also be important in antigen recognition; in those cases, AIRRscape could be modified to visualize changes outside of CDR3. With respect to identifying convergence, AIRRscape creates bins based on assigned germline V-gene families; thus, CDR3 topologies can indicate convergence even if antibodies have different germline V-genes within a family. While this definition of convergence is intended to cluster closely related germline genes such as IGHV3-53 &amp; IGHV3-66, it may be too broad in some cases. As an aid, we include the full V-gene assignments in the topology tip names, and we note that restricting the antibody list to one gene will limit searches to only convergences with matching V-genes. Also, while AIRRscape is focused on amino acid motifs, we acknowledge that amino acid sequence convergence is an imperfect predictor of functional convergence. Lastly, although AIRRscape can quickly and easily search for known antibody sequences, examine overall repertoire patterns, and find convergence, users currently cannot initiate searches for identical motifs across datasets, although new tools with this functionality are being developed [<xref rid="pcbi.1010052.ref063" ref-type="bibr">63</xref>].</p>
    <p>In summary, AIRRscape is a useful tool for quick and thorough exploration of large BCR repertoire datasets. Moreover, AIRRscape is novel among the suite of publicly available tools in visualizing convergence of antibody motifs. We have released the source code on GitHub so that interested research groups may use other datasets or incorporate more features. While the datasets from this study are pre-loaded, the tool allows users to visualize combinations of other AIRR datasets following AIRR Community standards. The code could be further modified to meet the desires of immuno-informaticians, virologists, and immunologists, for instance with respect to the CDR3 sequence identity thresholds, phylogenetic tree options, or color and visualization schemes. While our focus is on infectious disease, AIRRscape could be used for autoimmunity and cancer biology, for example to compare healthy vs. autoimmune or cancer patient repertoires. With minor code modifications, AIRRscape could also be used to visualize TCR repertoires and their CDR3 motifs. We hope that AIRRscape will be useful for the research community, and we encourage interested parties to contribute additional features that would further enable identification of convergent responses.</p>
  </sec>
  <sec id="sec012" sec-type="supplementary-material">
    <title>Supporting information</title>
    <supplementary-material id="pcbi.1010052.s001" position="float" content-type="local-data">
      <label>S1 Data</label>
      <caption>
        <title>Supplementary figures.</title>
        <p><bold>Fig A in S1 Data. SARS-CoV-2 convergent clonotypes to mAb C102 in the 3_4_11 bin.</bold> An 80% identity threshold is used to calculate convergence. Tips are colored by dataset source. Purple tips are published anti-COVID-19 antibodies from 12 different studies, dark gray tips are antibody sequences from a healthy donor BCR repertoire, and orange through brown shaded tips are antibody sequences from COVID-19 patient BCR repertoires. <bold>Fig B in S1 Data. SARS-CoV-2 convergent clonotypes to mAb C125 in the 1_3_16 bin</bold>. An 80% identity threshold is used to calculate convergence. Tips are colored by dataset source. Purple tips are published anti-COVID-19 antibodies from 7 different studies, dark gray tips are antibody sequences from a healthy donor BCR repertoire, and orange through brown shaded tips are antibody sequences from COVID-19 patient BCR repertoires. <bold>Fig C in S1 Data. SARS-CoV-2 convergent clonotypes to mAb BD-494 in the 3_6_11 bin.</bold> An 80% identity threshold is used to calculate convergence. Tips are colored by dataset source. Purple tips are published anti-COVID-19 antibodies from 15 different studies, dark gray tips are antibody sequences from a healthy donor BCR repertoire, and orange through brown shaded tips are antibody sequences from COVID-19 patient BCR repertoires. <bold>Fig D in S1 Data. AIRRscape heatmaps comparing anti-HIV-1 antibodies and bulk BCR repertoires of eight HIV-1 patients. Fig E in S1 Data. HIV-1 convergent clonotypes to mAb CAP351_6m_6041 (Setliff et al. 2018; Fig 3) in the 1_6_14 bin.</bold> A 70% identity threshold is used to calculate convergence. Tips are colored by dataset source. Purple tips are published anti-COVID-19 antibodies, and green shaded tips are antibody sequences from HIV-1 patient BCR repertoires. <bold>Fig F in S1 Data. AIRRscape heatmaps comparing isolated dengue plasmablasts and bulk BCR repertoires of dengue patients from Colombian and Nicaraguan cohorts. Fig G in S1 Data. Dengue convergent clonotypes to CF6 (Zanini et al. 2018).</bold> An 80% identity threshold is used to calculate convergence. Tips are colored by dataset source. Purple tips are plasmablast sequences reported by Zanini et al. (2018) isolated from two Colombian patients (d13 and d20), blue tips are antibody sequences from the BCR repertoire of patient d13, and gold tips are antibody sequences from a cohort of Nicaraguan patient BCR repertoires. <bold>Fig H in S1 Data. Dengue convergent clonotypes to CF7 (Zanini et al. 2018).</bold> An 80% identity threshold is used to calculate convergence. Tips are colored by dataset source. Purple tips are plasmablast sequences reported by Zanini et al. (2018) isolated from two Colombian patients (d13 and d20), blue tips are antibody sequences from the BCR repertoire of patient d13, and gold tips are antibody sequences from a cohort of Nicaraguan patient BCR repertoires. <bold>Fig I in S1 Data. Dengue convergent clonotypes to Parameswaran et al. (2018) motif ARQIGNWFDP similar to CF1 (Zanini et al. 2018).</bold> An 80% identity threshold is used to calculate convergence. Tips are colored by dataset source. Purple tips are plasmablast sequences reported by Zanini et al. (2018) isolated from two Colombian patients (d13 and d20), blue tips are antibody sequences from the BCR repertoire of patient d13, and gold tips are antibody sequences from a cohort of Nicaraguan patient BCR repertoires. <bold>Fig J in S1 Data. SARS-CoV-2, HIV-1, &amp; dengue convergent clonotypes to anti-SARS-CoV-2 mAb C102 in the 3_4_11 bin.</bold> An 80% identity threshold is used to calculate convergence. Tips are colored by dataset source. Purple tips are published anti-COVID-19 antibodies from 12 different studies, dark gray tips are antibody sequences from a healthy donor BCR repertoire, and orange through brown shaded tips are antibody sequences from COVID-19 patient BCR repertoires. Green shaded tips are antibody sequences from HIV-1 patient BCR repertoires. Gold tips are antibody sequences from a cohort of Nicaraguan dengue patient BCR repertoires. <bold>Fig K in S1 Data. SARS-CoV-2, HIV-1, &amp; dengue convergent clonotypes to anti-SARS-CoV-2 mAb BD-494 in the 3_6_11 bin.</bold> An 80% identity threshold is used to calculate convergence. Tips are colored by dataset source. Purple tips are published anti-COVID-19 antibodies from 15 different studies, dark gray tips are antibody sequences from a healthy donor BCR repertoire, and orange through brown shaded tips are antibody sequences from COVID-19 patient BCR repertoires. Green shaded tips are antibody sequences from HIV-1 patient BCR repertoires. Gold tips are antibody sequences from a cohort of Nicaraguan dengue patient BCR repertoires. <bold>Fig L in S1 Data. HIV-1 &amp; dengue convergent clonotypes to anti-HIV mAb 02-o (Setliff et al. 2018; Fig 4) in the 1_4_13 bin.</bold> An 80% identity threshold is used to calculate convergence. Tips are colored by dataset source. Purple tips are published anti-HIV-1 antibodies, while green shaded tips are antibody sequences from HIV-1 patient BCR repertoires. Blue tips are antibody sequences from the BCR repertoire of dengue patient d13, and gold tips are antibody sequences from a cohort of Nicaraguan dengue patient BCR repertoires. <bold>Fig M in S1 Data. SARS-CoV-2 &amp; dengue convergent clonotypes to anti-dengue mAb CF6 (Zanini et al. 2018) in the 1_4_13 bin.</bold> An 80% identity threshold is used to calculate convergence. Tips are colored by dataset source. Purple tips are plasmablast sequences reported by Zanini et al. (2018) isolated from two Colombian dengue patients (d13 and d20), blue tips are antibody sequences from the BCR repertoire of dengue patient d13, and gold tips are antibody sequences from a cohort of Nicaraguan dengue patient BCR repertoires. Brown shaded tips are antibody sequences from COVID-19 patient BCR repertoires.</p>
        <p>(PDF)</p>
      </caption>
      <media xlink:href="pcbi.1010052.s001.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack>
    <p>We would like to acknowledge members of the CZ Biohub Data Science platform for thoughtful discussion, and Sandra L. Schmid for comments on the manuscript. We would also like to thank Craig Kapfer and John Hanks for assistance with deploying AIRRscape onto the web.</p>
  </ack>
  <ref-list>
    <title>References</title>
    <ref id="pcbi.1010052.ref001">
      <label>1</label>
      <mixed-citation publication-type="journal"><name><surname>Briney</surname><given-names>B</given-names></name>, <name><surname>Inderbitzin</surname><given-names>A</given-names></name>, <name><surname>Joyce</surname><given-names>C</given-names></name>, <name><surname>Burton</surname><given-names>DR</given-names></name>. <article-title>Commonality despite exceptional diversity in the baseline human antibody repertoire</article-title>. <source>Nature</source>. <year>2019</year>;<volume>566</volume>: <fpage>393</fpage>–<lpage>397</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41586-019-0879-y</pub-id><?supplied-pmid 30664748?><pub-id pub-id-type="pmid">30664748</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref002">
      <label>2</label>
      <mixed-citation publication-type="journal"><name><surname>Raybould</surname><given-names>MIJ</given-names></name>, <name><surname>Rees</surname><given-names>AR</given-names></name>, <name><surname>Deane</surname><given-names>CM</given-names></name>. <article-title>Current strategies for detecting functional convergence across B-cell receptor repertoires</article-title>. <source>mAbs</source>. <year>2021</year>;<volume>13</volume>: <fpage>1996732</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/19420862.2021.1996732</pub-id><?supplied-pmid 34781829?><pub-id pub-id-type="pmid">34781829</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref003">
      <label>3</label>
      <mixed-citation publication-type="journal"><name><surname>Chaudhary</surname><given-names>N</given-names></name>, <name><surname>Wesemann</surname><given-names>DR</given-names></name>. <article-title>Analyzing Immunoglobulin Repertoires</article-title>. <source>Frontiers in Immunology</source>. <year>2018</year>;<volume>9</volume>: <fpage>462</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fimmu.2018.00462</pub-id><?supplied-pmid 29593723?><pub-id pub-id-type="pmid">29593723</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref004">
      <label>4</label>
      <mixed-citation publication-type="journal"><name><surname>Dunn-Walters</surname><given-names>D</given-names></name>, <name><surname>Townsend</surname><given-names>C</given-names></name>, <name><surname>Sinclair</surname><given-names>E</given-names></name>, <name><surname>Stewart</surname><given-names>A</given-names></name>. <article-title>Immunoglobulin gene analysis as a tool for investigating human immune responses</article-title>. <source>Immunological Reviews</source>. <year>2018</year>;<volume>284</volume>: <fpage>132</fpage>–<lpage>147</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/imr.12659</pub-id><?supplied-pmid 29944755?><pub-id pub-id-type="pmid">29944755</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref005">
      <label>5</label>
      <mixed-citation publication-type="journal"><name><surname>Wardemann</surname><given-names>H</given-names></name>, <name><surname>Busse</surname><given-names>CE</given-names></name>. <article-title>Novel Approaches to Analyze Immunoglobulin Repertoires</article-title>. <source>Trends in Immunology</source>. <year>2017</year>;<volume>38</volume>: <fpage>471</fpage>–<lpage>482</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.it.2017.05.003</pub-id><?supplied-pmid 28566130?><pub-id pub-id-type="pmid">28566130</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref006">
      <label>6</label>
      <mixed-citation publication-type="journal"><name><surname>Soto</surname><given-names>C</given-names></name>, <name><surname>Bombardi</surname><given-names>RG</given-names></name>, <name><surname>Branchizio</surname><given-names>A</given-names></name>, <name><surname>Kose</surname><given-names>N</given-names></name>, <name><surname>Matta</surname><given-names>P</given-names></name>, <name><surname>Sevy</surname><given-names>AM</given-names></name>, <etal>et al</etal>. <article-title>High frequency of shared clonotypes in human B cell receptor repertoires</article-title>. <source>Nature</source>. <year>2019</year>;<volume>566</volume>: <fpage>398</fpage>–<lpage>402</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41586-019-0934-8</pub-id><?supplied-pmid 30760926?><pub-id pub-id-type="pmid">30760926</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref007">
      <label>7</label>
      <mixed-citation publication-type="journal"><name><surname>Setliff</surname><given-names>I</given-names></name>, <name><surname>McDonnell</surname><given-names>WJ</given-names></name>, <name><surname>Raju</surname><given-names>N</given-names></name>, <name><surname>Bombardi</surname><given-names>RG</given-names></name>, <name><surname>Murji</surname><given-names>AA</given-names></name>, <name><surname>Scheepers</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Multi-Donor Longitudinal Antibody Repertoire Sequencing Reveals the Existence of Public Antibody Clonotypes in HIV-1 Infection</article-title>. <source>Cell Host &amp; Microbe</source>. <year>2018</year>;<volume>23</volume>: <fpage>845</fpage>–<lpage>854.e6</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.chom.2018.05.001</pub-id><?supplied-pmid 29861170?><pub-id pub-id-type="pmid">29861170</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref008">
      <label>8</label>
      <mixed-citation publication-type="journal"><name><surname>Miho</surname><given-names>E</given-names></name>, <name><surname>Yermanos</surname><given-names>A</given-names></name>, <name><surname>Weber</surname><given-names>CR</given-names></name>, <name><surname>Berger</surname><given-names>CT</given-names></name>, <name><surname>Reddy</surname><given-names>ST</given-names></name>, <name><surname>Greiff</surname><given-names>V</given-names></name>. <article-title>Computational Strategies for Dissecting the High-Dimensional Complexity of Adaptive Immune Repertoires</article-title>. <source>Front Immunol</source>. <year>2018</year>;<fpage>9</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fimmu.2018.00224</pub-id><?supplied-pmid 29515569?><pub-id pub-id-type="pmid">29403493</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref009">
      <label>9</label>
      <mixed-citation publication-type="journal"><name><surname>Rubelt</surname><given-names>F</given-names></name>, <name><surname>Bolen</surname><given-names>CR</given-names></name>, <name><surname>McGuire</surname><given-names>HM</given-names></name>, <name><surname>Heiden</surname><given-names>JAV</given-names></name>, <name><surname>Gadala-Maria</surname><given-names>D</given-names></name>, <name><surname>Levin</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Individual heritable differences result in unique cell lymphocyte receptor repertoires of naïve and antigen-experienced cells</article-title>. <source>Nature Communications</source>. <year>2016</year>;<volume>7</volume>: <fpage>11112</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/ncomms11112</pub-id><?supplied-pmid 27005435?><pub-id pub-id-type="pmid">27005435</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref010">
      <label>10</label>
      <mixed-citation publication-type="journal"><name><surname>Foglierini</surname><given-names>M</given-names></name>, <name><surname>Pappas</surname><given-names>L</given-names></name>, <name><surname>Lanzavecchia</surname><given-names>A</given-names></name>, <name><surname>Corti</surname><given-names>D</given-names></name>, <name><surname>Perez</surname><given-names>L</given-names></name>. <article-title>AncesTree: An interactive immunoglobulin lineage tree visualizer</article-title>. <source>PLOS Computational Biology</source>. <year>2020</year>;<volume>16</volume>: <fpage>e1007731</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pcbi.1007731</pub-id><?supplied-pmid 32649725?><pub-id pub-id-type="pmid">32649725</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref011">
      <label>11</label>
      <mixed-citation publication-type="journal"><name><surname>Avram</surname><given-names>O</given-names></name>, <name><surname>Vaisman-Mentesh</surname><given-names>A</given-names></name>, <name><surname>Yehezkel</surname><given-names>D</given-names></name>, <name><surname>Ashkenazy</surname><given-names>H</given-names></name>, <name><surname>Pupko</surname><given-names>T</given-names></name>, <name><surname>Wine</surname><given-names>Y</given-names></name>. <article-title>ASAP—A Webserver for Immunoglobulin-Sequencing Analysis Pipeline</article-title>. <source>Frontiers in Immunology</source>. <year>2018</year>;<fpage>9</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fimmu.2018.01686</pub-id><?supplied-pmid 30105017?><pub-id pub-id-type="pmid">29403493</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref012">
      <label>12</label>
      <mixed-citation publication-type="journal"><name><surname>Margreitter</surname><given-names>C</given-names></name>, <name><surname>Lu</surname><given-names>H-C</given-names></name>, <name><surname>Townsend</surname><given-names>C</given-names></name>, <name><surname>Stewart</surname><given-names>A</given-names></name>, <name><surname>Dunn-Walters</surname><given-names>DK</given-names></name>, <name><surname>Fraternali</surname><given-names>F</given-names></name>. <article-title>BRepertoire: a user-friendly web server for analysing antibody repertoire data</article-title>. <source>Nucleic Acids Research</source>. <year>2018</year>;<volume>46</volume>: <fpage>W264</fpage>–<lpage>W270</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gky276</pub-id><?supplied-pmid 29668996?><pub-id pub-id-type="pmid">29668996</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref013">
      <label>13</label>
      <mixed-citation publication-type="journal"><name><surname>Team</surname><given-names>ImmunoMind</given-names></name>. <source>immunarch: An R Package for Painless Bioinformatics Analysis of T-Cell and B-Cell Immune Repertoires</source>. <year>2019</year>. Available: <pub-id pub-id-type="doi">10.5281/zenodo.3367200</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref014">
      <label>14</label>
      <mixed-citation publication-type="journal"><name><surname>Weber</surname><given-names>CR</given-names></name>, <name><surname>Rubio</surname><given-names>T</given-names></name>, <name><surname>Wang</surname><given-names>L</given-names></name>, <name><surname>Zhang</surname><given-names>W</given-names></name>, <name><surname>Robert</surname><given-names>PA</given-names></name>, <name><surname>Akbar</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Reference-based comparison of adaptive immune receptor repertoires</article-title>. <source>Cell Reports Methods</source>. <year>2022</year>;<fpage>2</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.crmeth.2022.100269</pub-id><?supplied-pmid 36046619?><pub-id pub-id-type="pmid">36046619</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref015">
      <label>15</label>
      <mixed-citation publication-type="journal"><name><surname>Ralph</surname><given-names>DK</given-names></name>, <name><surname>Matsen</surname><given-names>FAI</given-names></name>. <article-title>Using B cell receptor lineage structures to predict affinity</article-title>. <source>PLOS Computational Biology</source>. <year>2020</year>;<volume>16</volume>: <fpage>e1008391</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pcbi.1008391</pub-id><?supplied-pmid 33175831?><pub-id pub-id-type="pmid">33175831</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref016">
      <label>16</label>
      <mixed-citation publication-type="journal"><name><surname>Avram</surname><given-names>O</given-names></name>, <name><surname>Kigel</surname><given-names>A</given-names></name>, <name><surname>Vaisman-Mentesh</surname><given-names>A</given-names></name>, <name><surname>Kligsberg</surname><given-names>S</given-names></name>, <name><surname>Rosenstein</surname><given-names>S</given-names></name>, <name><surname>Dror</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>PASA: Proteomic analysis of serum antibodies web server</article-title>. <source>PLOS Computational Biology</source>. <year>2021</year>;<volume>17</volume>: <fpage>e1008607</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pcbi.1008607</pub-id><?supplied-pmid 33493161?><pub-id pub-id-type="pmid">33493161</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref017">
      <label>17</label>
      <mixed-citation publication-type="journal"><name><surname>Olson</surname><given-names>BJ</given-names></name>, <name><surname>Moghimi</surname><given-names>P</given-names></name>, <name><surname>Schramm</surname><given-names>CA</given-names></name>, <name><surname>Obraztsova</surname><given-names>A</given-names></name>, <name><surname>Ralph</surname><given-names>D</given-names></name>, <name><surname>Vander Heiden</surname><given-names>JA</given-names></name>, <etal>et al</etal>. <article-title>sumrep: A Summary Statistic Framework for Immune Receptor Repertoire Comparison and Model Validation</article-title>. <source>Front Immunol</source>. <year>2019</year>;<fpage>10</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fimmu.2019.02533</pub-id><?supplied-pmid 31736960?><pub-id pub-id-type="pmid">30723470</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref018">
      <label>18</label>
      <mixed-citation publication-type="journal"><name><surname>Omer</surname><given-names>A</given-names></name>, <name><surname>Shemesh</surname><given-names>O</given-names></name>, <name><surname>Peres</surname><given-names>A</given-names></name>, <name><surname>Polak</surname><given-names>P</given-names></name>, <name><surname>Shepherd</surname><given-names>AJ</given-names></name>, <name><surname>Watson</surname><given-names>CT</given-names></name>, <etal>et al</etal>. <article-title>VDJbase: an adaptive immune receptor genotype and haplotype database</article-title>. <source>Nucleic Acids Res</source>. <year>2020</year>;<volume>48</volume>: <fpage>D1051</fpage>–<lpage>D1056</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gkz872</pub-id><?supplied-pmid 31602484?><pub-id pub-id-type="pmid">31602484</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref019">
      <label>19</label>
      <mixed-citation publication-type="journal"><name><surname>Christley</surname><given-names>S</given-names></name>, <name><surname>Scarborough</surname><given-names>W</given-names></name>, <name><surname>Salinas</surname><given-names>E</given-names></name>, <name><surname>Rounds</surname><given-names>WH</given-names></name>, <name><surname>Toby</surname><given-names>IT</given-names></name>, <name><surname>Fonner</surname><given-names>JM</given-names></name>, <etal>et al</etal>. <article-title>VDJServer: A Cloud-Based Analysis Portal and Data Commons for Immune Repertoire Sequences and Rearrangements</article-title>. <source>Frontiers in Immunology</source>. <year>2018</year>;<fpage>9</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fimmu.2018.00976</pub-id><?supplied-pmid 29867956?><pub-id pub-id-type="pmid">29403493</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref020">
      <label>20</label>
      <mixed-citation publication-type="journal"><name><surname>Shugay</surname><given-names>M</given-names></name>, <name><surname>Bagaev</surname><given-names>DV</given-names></name>, <name><surname>Turchaninova</surname><given-names>MA</given-names></name>, <name><surname>Bolotin</surname><given-names>DA</given-names></name>, <name><surname>Britanova</surname><given-names>OV</given-names></name>, <name><surname>Putintseva</surname><given-names>EV</given-names></name>, <etal>et al</etal>. <article-title>VDJtools: Unifying Post-analysis of T Cell Receptor Repertoires</article-title>. <source>PLOS Computational Biology</source>. <year>2015</year>;<volume>11</volume>: <fpage>e1004503</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pcbi.1004503</pub-id><?supplied-pmid 26606115?><pub-id pub-id-type="pmid">26606115</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref021">
      <label>21</label>
      <mixed-citation publication-type="journal"><name><surname>Bagaev</surname><given-names>DV</given-names></name>, <name><surname>Zvyagin</surname><given-names>IV</given-names></name>, <name><surname>Putintseva</surname><given-names>EV</given-names></name>, <name><surname>Izraelson</surname><given-names>M</given-names></name>, <name><surname>Britanova</surname><given-names>OV</given-names></name>, <name><surname>Chudakov</surname><given-names>DM</given-names></name>, <etal>et al</etal>. <article-title>VDJviz: a versatile browser for immunogenomics data</article-title>. <source>BMC Genomics</source>. <year>2016</year>;<volume>17</volume>: <fpage>453</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12864-016-2799-7</pub-id><?supplied-pmid 27297497?><pub-id pub-id-type="pmid">27297497</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref022">
      <label>22</label>
      <mixed-citation publication-type="journal"><name><surname>Muggen</surname><given-names>AF</given-names></name>, <name><surname>de Jong</surname><given-names>M</given-names></name>, <name><surname>Wolvers-Tettero</surname><given-names>ILM</given-names></name>, <name><surname>Kallemeijn</surname><given-names>MJ</given-names></name>, <name><surname>Teodósio</surname><given-names>C</given-names></name>, <name><surname>Darzentas</surname><given-names>N</given-names></name>, <etal>et al</etal>. <article-title>The presence of CLL-associated stereotypic B cell receptors in the normal BCR repertoire from healthy individuals increases with age</article-title>. <source>Immun Ageing</source>. <year>2019</year>;<volume>16</volume>: <fpage>22</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12979-019-0163-x</pub-id><?supplied-pmid 31485252?><pub-id pub-id-type="pmid">31485252</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref023">
      <label>23</label>
      <mixed-citation publication-type="journal"><name><surname>Schultheiß</surname><given-names>C</given-names></name>, <name><surname>Paschold</surname><given-names>L</given-names></name>, <name><surname>Simnica</surname><given-names>D</given-names></name>, <name><surname>Mohme</surname><given-names>M</given-names></name>, <name><surname>Willscher</surname><given-names>E</given-names></name>, <name><surname>von Wenserski</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Next-Generation Sequencing of T and B Cell Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of Disease</article-title>. <source>Immunity</source>. <year>2020</year>;<volume>53</volume>: <fpage>442</fpage>–<lpage>455</lpage>.e4. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.immuni.2020.06.024</pub-id><?supplied-pmid 32668194?><pub-id pub-id-type="pmid">32668194</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref024">
      <label>24</label>
      <mixed-citation publication-type="journal"><name><surname>Horns</surname><given-names>F</given-names></name>, <name><surname>Vollmers</surname><given-names>C</given-names></name>, <name><surname>Croote</surname><given-names>D</given-names></name>, <name><surname>Mackey</surname><given-names>SF</given-names></name>, <name><surname>Swan</surname><given-names>GE</given-names></name>, <name><surname>Dekker</surname><given-names>CL</given-names></name>, <etal>et al</etal>. <article-title>Lineage tracing of human B cells reveals the in vivo landscape of human antibody class switching</article-title>. <source>Neher RA</source>, editor. eLife. <year>2016</year>;<volume>5</volume>: <fpage>e16578</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.7554/eLife.16578</pub-id><?supplied-pmid 27481325?><pub-id pub-id-type="pmid">27481325</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref025">
      <label>25</label>
      <mixed-citation publication-type="journal"><name><surname>Chang</surname><given-names>W</given-names></name>, <name><surname>Cheng</surname><given-names>J</given-names></name>, <name><surname>Allaire</surname><given-names>JJ</given-names></name>, <name><surname>Xie</surname><given-names>Y</given-names></name>, <name><surname>McPherson</surname><given-names>J</given-names></name>. <source>shiny: Web Application Framework for R</source>. <year>2020</year>. Available: <ext-link xlink:href="https://CRAN.R-project.org/package=shiny" ext-link-type="uri">https://CRAN.R-project.org/package=shiny</ext-link></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref026">
      <label>26</label>
      <mixed-citation publication-type="journal"><name><surname>Galson</surname><given-names>JD</given-names></name>, <name><surname>Schaetzle</surname><given-names>S</given-names></name>, <name><surname>Bashford-Rogers</surname><given-names>RJM</given-names></name>, <name><surname>Raybould</surname><given-names>MIJ</given-names></name>, <name><surname>Kovaltsuk</surname><given-names>A</given-names></name>, <name><surname>Kilpatrick</surname><given-names>GJ</given-names></name>, <etal>et al</etal>. <article-title>Deep Sequencing of B Cell Receptor Repertoires From COVID-19 Patients Reveals Strong Convergent Immune Signatures</article-title>. <source>Frontiers in Immunology</source>. <year>2020</year>;<fpage>11</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fimmu.2020.605170</pub-id><?supplied-pmid 33384691?><pub-id pub-id-type="pmid">32082309</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref027">
      <label>27</label>
      <mixed-citation publication-type="journal"><name><surname>Robbiani</surname><given-names>DF</given-names></name>, <name><surname>Gaebler</surname><given-names>C</given-names></name>, <name><surname>Muecksch</surname><given-names>F</given-names></name>, <name><surname>Lorenzi</surname><given-names>JCC</given-names></name>, <name><surname>Wang</surname><given-names>Z</given-names></name>, <name><surname>Cho</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Convergent antibody responses to SARS-CoV-2 in convalescent individuals</article-title>. <source>Nature</source>. <year>2020</year>;<volume>584</volume>: <fpage>437</fpage>–<lpage>442</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41586-020-2456-9</pub-id><?supplied-pmid 32555388?><pub-id pub-id-type="pmid">32555388</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref028">
      <label>28</label>
      <mixed-citation publication-type="journal"><name><surname>Yuan</surname><given-names>M</given-names></name>, <name><surname>Liu</surname><given-names>H</given-names></name>, <name><surname>Wu</surname><given-names>NC</given-names></name>, <name><surname>Lee</surname><given-names>C-CD</given-names></name>, <name><surname>Zhu</surname><given-names>X</given-names></name>, <name><surname>Zhao</surname><given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Structural basis of a shared antibody response to SARS-CoV-2</article-title>. <source>Science</source>. <year>2020</year>;<volume>369</volume>: <fpage>1119</fpage>–<lpage>1123</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/science.abd2321</pub-id><?supplied-pmid 32661058?><pub-id pub-id-type="pmid">32661058</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref029">
      <label>29</label>
      <mixed-citation publication-type="journal"><name><surname>Durham</surname><given-names>ND</given-names></name>, <name><surname>Agrawal</surname><given-names>A</given-names></name>, <name><surname>Waltari</surname><given-names>E</given-names></name>, <name><surname>Croote</surname><given-names>D</given-names></name>, <name><surname>Zanini</surname><given-names>F</given-names></name>, <name><surname>Fouch</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics</article-title>. <source>eLife</source>. <year>2019</year>;<volume>8</volume>: <fpage>e52384</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.7554/eLife.52384</pub-id><?supplied-pmid 31820734?><pub-id pub-id-type="pmid">31820734</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref030">
      <label>30</label>
      <mixed-citation publication-type="journal"><name><surname>Parameswaran</surname><given-names>P</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Roskin</surname><given-names>KM</given-names></name>, <name><surname>Jackson</surname><given-names>KKL</given-names></name>, <name><surname>Dixit</surname><given-names>VP</given-names></name>, <name><surname>Lee</surname><given-names>J-Y</given-names></name>, <etal>et al</etal>. <article-title>Convergent Antibody Signatures in Human Dengue</article-title>. <source>Cell Host &amp; Microbe</source>. <year>2013</year>;<volume>13</volume>: <fpage>691</fpage>–<lpage>700</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.chom.2013.05.008</pub-id><?supplied-pmid 23768493?><pub-id pub-id-type="pmid">23768493</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref031">
      <label>31</label>
      <mixed-citation publication-type="journal"><name><surname>Zanini</surname><given-names>F</given-names></name>, <name><surname>Robinson</surname><given-names>ML</given-names></name>, <name><surname>Croote</surname><given-names>D</given-names></name>, <name><surname>Sahoo</surname><given-names>MK</given-names></name>, <name><surname>Sanz</surname><given-names>AM</given-names></name>, <name><surname>Ortiz-Lasso</surname><given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Virus-inclusive single-cell RNA sequencing reveals the molecular signature of progression to severe dengue</article-title>. <source>PNAS</source>. <year>2018</year>;<volume>115</volume>: <fpage>E12363</fpage>–<lpage>E12369</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1073/pnas.1813819115</pub-id><?supplied-pmid 30530648?><pub-id pub-id-type="pmid">30530648</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref032">
      <label>32</label>
      <mixed-citation publication-type="journal"><name><surname>Breden</surname><given-names>F</given-names></name>, <name><surname>Luning Prak</surname><given-names>ET</given-names></name>, <name><surname>Peters</surname><given-names>B</given-names></name>, <name><surname>Rubelt</surname><given-names>F</given-names></name>, <name><surname>Schramm</surname><given-names>CA</given-names></name>, <name><surname>Busse</surname><given-names>CE</given-names></name>, <etal>et al</etal>. <article-title>Reproducibility and Reuse of Adaptive Immune Receptor Repertoire Data</article-title>. <source>Frontiers in Immunology</source>. <year>2017</year>;<volume>8</volume>: <fpage>1418</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fimmu.2017.01418</pub-id><?supplied-pmid 29163494?><pub-id pub-id-type="pmid">29163494</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref033">
      <label>33</label>
      <mixed-citation publication-type="journal"><name><surname>Rubelt</surname><given-names>F</given-names></name>, <name><surname>Busse</surname><given-names>CE</given-names></name>, <name><surname>Bukhari</surname><given-names>SAC</given-names></name>, <name><surname>Bürckert</surname><given-names>J-P</given-names></name>, <name><surname>Mariotti-Ferrandiz</surname><given-names>E</given-names></name>, <name><surname>Cowell</surname><given-names>LG</given-names></name>, <etal>et al</etal>. <article-title>Adaptive Immune Receptor Repertoire Community recommendations for sharing immune-repertoire sequencing data</article-title>. <source>Nat Immunol</source>. <year>2017</year>;<volume>18</volume>: <fpage>1274</fpage>–<lpage>1278</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/ni.3873</pub-id><?supplied-pmid 29144493?><pub-id pub-id-type="pmid">29144493</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref034">
      <label>34</label>
      <mixed-citation publication-type="journal"><name><surname>Corrie</surname><given-names>BD</given-names></name>, <name><surname>Marthandan</surname><given-names>N</given-names></name>, <name><surname>Zimonja</surname><given-names>B</given-names></name>, <name><surname>Jaglale</surname><given-names>J</given-names></name>, <name><surname>Zhou</surname><given-names>Y</given-names></name>, <name><surname>Barr</surname><given-names>E</given-names></name>, <etal>et al</etal>. <article-title>iReceptor: A platform for querying and analyzing antibody/B-cell and T-cell receptor repertoire data across federated repositories</article-title>. <source>Immunological Reviews</source>. <year>2018</year>;<volume>284</volume>: <fpage>24</fpage>–<lpage>41</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/imr.12666</pub-id><?supplied-pmid 29944754?><pub-id pub-id-type="pmid">29944754</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref035">
      <label>35</label>
      <mixed-citation publication-type="journal"><name><surname>Kovaltsuk</surname><given-names>A</given-names></name>, <name><surname>Leem</surname><given-names>J</given-names></name>, <name><surname>Kelm</surname><given-names>S</given-names></name>, <name><surname>Snowden</surname><given-names>J</given-names></name>, <name><surname>Deane</surname><given-names>CM</given-names></name>, <name><surname>Krawczyk</surname><given-names>K</given-names></name>. <article-title>Observed Antibody Space: A Resource for Data Mining Next-Generation Sequencing of Antibody Repertoires</article-title>. <source>The Journal of Immunology</source>. <year>2018</year>;<volume>201</volume>: <fpage>2502</fpage>–<lpage>2509</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.4049/jimmunol.1800708</pub-id><?supplied-pmid 30217829?><pub-id pub-id-type="pmid">30217829</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref036">
      <label>36</label>
      <mixed-citation publication-type="journal"><name><surname>Olsen</surname><given-names>TH</given-names></name>, <name><surname>Boyles</surname><given-names>F</given-names></name>, <name><surname>Deane</surname><given-names>CM</given-names></name>. <article-title>Observed Antibody Space: A diverse database of cleaned, annotated, and translated unpaired and paired antibody sequences</article-title>. <source>Protein Science</source>. <year>2021</year>;<volume>2021</volume>: <fpage>1</fpage>–<lpage>6</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/pro.4205</pub-id><?supplied-pmid 34655133?><pub-id pub-id-type="pmid">34655133</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref037">
      <label>37</label>
      <mixed-citation publication-type="journal"><name><surname>Kuri-Cervantes</surname><given-names>L</given-names></name>, <name><surname>Pampena</surname><given-names>MB</given-names></name>, <name><surname>Meng</surname><given-names>W</given-names></name>, <name><surname>Rosenfeld</surname><given-names>AM</given-names></name>, <name><surname>Ittner</surname><given-names>CAG</given-names></name>, <name><surname>Weisman</surname><given-names>AR</given-names></name>, <etal>et al</etal>. <article-title>Comprehensive mapping of immune perturbations associated with severe COVID-19</article-title>. <source>Science Immunology</source>. <year>2020</year>;<volume>5</volume>: <fpage>eabd7114</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/sciimmunol.abd7114</pub-id><?supplied-pmid 32669287?><pub-id pub-id-type="pmid">32669287</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref038">
      <label>38</label>
      <mixed-citation publication-type="journal"><name><surname>Nielsen</surname><given-names>SCA</given-names></name>, <name><surname>Yang</surname><given-names>F</given-names></name>, <name><surname>Jackson</surname><given-names>KJL</given-names></name>, <name><surname>Hoh</surname><given-names>RA</given-names></name>, <name><surname>Röltgen</surname><given-names>K</given-names></name>, <name><surname>Jean</surname><given-names>GH</given-names></name>, <etal>et al</etal>. <article-title>Human B Cell Clonal Expansion and Convergent Antibody Responses to SARS-CoV-2</article-title>. <source>Cell Host &amp; Microbe</source>. <year>2020</year>;<volume>28</volume>: <fpage>516</fpage>–<lpage>525</lpage>.e5. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.chom.2020.09.002</pub-id><?supplied-pmid 32941787?><pub-id pub-id-type="pmid">32941787</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref039">
      <label>39</label>
      <mixed-citation publication-type="journal"><name><surname>Waltari</surname><given-names>E</given-names></name>, <name><surname>Jia</surname><given-names>M</given-names></name>, <name><surname>Jiang</surname><given-names>CS</given-names></name>, <name><surname>Lu</surname><given-names>H</given-names></name>, <name><surname>Huang</surname><given-names>J</given-names></name>, <name><surname>Fernandez</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>5′ Rapid Amplification of cDNA Ends and Illumina MiSeq Reveals B Cell Receptor Features in Healthy Adults, Adults With Chronic HIV-1 Infection, Cord Blood, and Humanized Mice</article-title>. <source>Frontiers in Immunology</source>. <year>2018</year>;<volume>9</volume>: <fpage>628</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fimmu.2018.00628</pub-id><?supplied-pmid 29632541?><pub-id pub-id-type="pmid">29632541</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref040">
      <label>40</label>
      <mixed-citation publication-type="journal"><name><surname>Waltari</surname><given-names>E</given-names></name>, <name><surname>McGeever</surname><given-names>A</given-names></name>, <name><surname>Friedland</surname><given-names>N</given-names></name>, <name><surname>Kim</surname><given-names>PS</given-names></name>, <name><surname>McCutcheon</surname><given-names>KM</given-names></name>. <article-title>Functional enrichment and analysis of Antigen-Specific memory B cell antibody repertoires in PBMCs</article-title>. <source>Frontiers in immunology</source>. <year>2019</year>;<volume>10</volume>: <fpage>1452</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fimmu.2019.01452</pub-id><?supplied-pmid 31293598?><pub-id pub-id-type="pmid">31293598</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref041">
      <label>41</label>
      <mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>X</given-names></name>, <name><surname>Zhang</surname><given-names>Z</given-names></name>, <name><surname>Schramm</surname><given-names>CA</given-names></name>, <name><surname>Joyce</surname><given-names>MG</given-names></name>, <name><surname>Do Kwon</surname><given-names>Y</given-names></name>, <name><surname>Zhou</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection</article-title>. <source>Cell</source>. <year>2015</year>;<volume>161</volume>: <fpage>470</fpage>–<lpage>485</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cell.2015.03.004</pub-id><?supplied-pmid 25865483?><pub-id pub-id-type="pmid">25865483</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref042">
      <label>42</label>
      <mixed-citation publication-type="journal"><name><surname>Raybould</surname><given-names>MIJ</given-names></name>, <name><surname>Kovaltsuk</surname><given-names>A</given-names></name>, <name><surname>Marks</surname><given-names>C</given-names></name>, <name><surname>Deane</surname><given-names>CM</given-names></name>. <article-title>CoV-AbDab: the coronavirus antibody database</article-title>. <source>Bioinformatics</source>. <year>2020</year>;<volume>37</volume>: <fpage>734</fpage>–<lpage>735</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/bioinformatics/btaa739</pub-id><?supplied-pmid 32805021?><pub-id pub-id-type="pmid">32805021</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref043">
      <label>43</label>
      <mixed-citation publication-type="journal"><name><surname>Mahajan</surname><given-names>S</given-names></name>, <name><surname>Vita</surname><given-names>R</given-names></name>, <name><surname>Shackelford</surname><given-names>D</given-names></name>, <name><surname>Lane</surname><given-names>J</given-names></name>, <name><surname>Schulten</surname><given-names>V</given-names></name>, <name><surname>Zarebski</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Epitope Specific Antibodies and T Cell Receptors in the Immune Epitope Database</article-title>. <source>Front Immunol</source>. <year>2018</year>;<fpage>9</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fimmu.2018.02688</pub-id><?supplied-pmid 30515166?><pub-id pub-id-type="pmid">29403493</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref044">
      <label>44</label>
      <mixed-citation publication-type="journal"><name><surname>Yoon</surname><given-names>H</given-names></name>, <name><surname>Macke</surname><given-names>J</given-names></name>, <name><surname>West</surname><given-names>AP</given-names></name>, <name><surname>Foley</surname><given-names>B</given-names></name>, <name><surname>Bjorkman</surname><given-names>PJ</given-names></name>, <name><surname>Korber</surname><given-names>B</given-names></name>, <etal>et al</etal>. <article-title>CATNAP: a tool to compile, analyze and tally neutralizing antibody panels</article-title>. <source>Nucleic Acids Res</source>. <year>2015</year>;<volume>43</volume>: <fpage>W213</fpage>–<lpage>W219</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gkv404</pub-id><?supplied-pmid 26044712?><pub-id pub-id-type="pmid">26044712</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref045">
      <label>45</label>
      <mixed-citation publication-type="journal"><name><surname>Yacoob</surname><given-names>C</given-names></name>, <name><surname>Pancera</surname><given-names>M</given-names></name>, <name><surname>Vigdorovich</surname><given-names>V</given-names></name>, <name><surname>Oliver</surname><given-names>BG</given-names></name>, <name><surname>Glenn</surname><given-names>JA</given-names></name>, <name><surname>Feng</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Differences in Allelic Frequency and CDRH3 Region Limit the Engagement of HIV Env Immunogens by Putative VRC01 Neutralizing Antibody Precursors</article-title>. <source>Cell Reports</source>. <year>2016</year>;<volume>17</volume>: <fpage>1560</fpage>–<lpage>1570</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.celrep.2016.10.017</pub-id><?supplied-pmid 27806295?><pub-id pub-id-type="pmid">27806295</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref046">
      <label>46</label>
      <mixed-citation publication-type="journal"><name><surname>Vander Heiden</surname><given-names>JA</given-names></name>, <name><surname>Yaari</surname><given-names>G</given-names></name>, <name><surname>Uduman</surname><given-names>M</given-names></name>, <name><surname>Stern</surname><given-names>JN</given-names></name>, <name><surname>O’Connor</surname><given-names>KC</given-names></name>, <name><surname>Hafler</surname><given-names>DA</given-names></name>, <etal>et al</etal>. <article-title>pRESTO: a toolkit for processing high-throughput sequencing raw reads of lymphocyte receptor repertoires</article-title>. <source>Bioinformatics</source>. <year>2014</year>;<volume>30</volume>: <fpage>1930</fpage>–<lpage>1932</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/bioinformatics/btu138</pub-id><?supplied-pmid 24618469?><pub-id pub-id-type="pmid">24618469</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref047">
      <label>47</label>
      <mixed-citation publication-type="journal"><name><surname>Gupta</surname><given-names>NT</given-names></name>, <name><surname>Vander Heiden</surname><given-names>JA</given-names></name>, <name><surname>Uduman</surname><given-names>M</given-names></name>, <name><surname>Gadala-Maria</surname><given-names>D</given-names></name>, <name><surname>Yaari</surname><given-names>G</given-names></name>, <name><surname>Kleinstein</surname><given-names>SH</given-names></name>. <article-title>Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data</article-title>. <source>Bioinformatics</source>. <year>2015</year>;<volume>31</volume>: <fpage>3356</fpage>–<lpage>3358</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/bioinformatics/btv359</pub-id><?supplied-pmid 26069265?><pub-id pub-id-type="pmid">26069265</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref048">
      <label>48</label>
      <mixed-citation publication-type="journal"><name><surname>Zhou</surname><given-names>JQ</given-names></name>, <name><surname>Kleinstein</surname><given-names>SH</given-names></name>. <article-title>Cutting Edge: Ig H Chains Are Sufficient to Determine Most B Cell Clonal Relationships</article-title>. <source>The Journal of Immunology</source>. <year>2019</year>;<volume>203</volume>: <fpage>1687</fpage>–<lpage>1692</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.4049/jimmunol.1900666</pub-id><?supplied-pmid 31484734?><pub-id pub-id-type="pmid">31484734</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref049">
      <label>49</label>
      <mixed-citation publication-type="journal"><name><surname>Xu</surname><given-names>JL</given-names></name>, <name><surname>Davis</surname><given-names>MM</given-names></name>. <article-title>Diversity in the CDR3 Region of VH Is Sufficient for Most Antibody Specificities</article-title>. <source>Immunity</source>. <year>2000</year>;<volume>13</volume>: <fpage>37</fpage>–<lpage>45</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s1074-7613(00)00006-6</pub-id><?supplied-pmid 10933393?><pub-id pub-id-type="pmid">10933393</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref050">
      <label>50</label>
      <mixed-citation publication-type="journal"><name><surname>Holder</surname><given-names>M</given-names></name>, <name><surname>Lewis</surname><given-names>PO</given-names></name>. <article-title>Phylogeny estimation: traditional and Bayesian approaches</article-title>. <source>Nat Rev Genet</source>. <year>2003</year>;<volume>4</volume>: <fpage>275</fpage>–<lpage>284</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nrg1044</pub-id><?supplied-pmid 12671658?><pub-id pub-id-type="pmid">12671658</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref051">
      <label>51</label>
      <mixed-citation publication-type="journal"><name><surname>Schliep</surname><given-names>KP</given-names></name>. <article-title>phangorn: phylogenetic analysis in R</article-title>. <source>Bioinformatics</source>. <year>2011</year>;<volume>27</volume>: <fpage>592</fpage>–<lpage>593</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/bioinformatics/btq706</pub-id><?supplied-pmid 21169378?><pub-id pub-id-type="pmid">21169378</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref052">
      <label>52</label>
      <mixed-citation publication-type="journal"><name><surname>Scheid</surname><given-names>JF</given-names></name>, <name><surname>Mouquet</surname><given-names>H</given-names></name>, <name><surname>Feldhahn</surname><given-names>N</given-names></name>, <name><surname>Seaman</surname><given-names>MS</given-names></name>, <name><surname>Velinzon</surname><given-names>K</given-names></name>, <name><surname>Pietzsch</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals</article-title>. <source>Nature</source>. <year>2009</year>;<volume>458</volume>: <fpage>636</fpage>–<lpage>640</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nature07930</pub-id><?supplied-pmid 19287373?><pub-id pub-id-type="pmid">19287373</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref053">
      <label>53</label>
      <mixed-citation publication-type="journal"><name><surname>Sok</surname><given-names>D</given-names></name>, <name><surname>Burton</surname><given-names>DR</given-names></name>. <article-title>Recent progress in broadly neutralizing antibodies to HIV</article-title>. <source>Nat Immunol</source>. <year>2018</year>;<volume>19</volume>: <fpage>1179</fpage>–<lpage>1188</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41590-018-0235-7</pub-id><?supplied-pmid 30333615?><pub-id pub-id-type="pmid">30333615</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref054">
      <label>54</label>
      <mixed-citation publication-type="journal"><name><surname>Kreer</surname><given-names>C</given-names></name>, <name><surname>Zehner</surname><given-names>M</given-names></name>, <name><surname>Weber</surname><given-names>T</given-names></name>, <name><surname>Ercanoglu</surname><given-names>MS</given-names></name>, <name><surname>Gieselmann</surname><given-names>L</given-names></name>, <name><surname>Rohde</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients</article-title>. <source>Cell</source>. <year>2020</year>;<volume>182</volume>: <fpage>843</fpage>–<lpage>854</lpage>.e12. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cell.2020.06.044</pub-id><?supplied-pmid 32673567?><pub-id pub-id-type="pmid">32673567</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref055">
      <label>55</label>
      <mixed-citation publication-type="journal"><name><surname>Kreer</surname><given-names>C</given-names></name>, <name><surname>Gruell</surname><given-names>H</given-names></name>, <name><surname>Mora</surname><given-names>T</given-names></name>, <name><surname>Walczak</surname><given-names>AM</given-names></name>, <name><surname>Klein</surname><given-names>F</given-names></name>. <article-title>Exploiting B Cell Receptor Analyses to Inform on HIV-1 Vaccination Strategies</article-title>. <source>Vaccines</source>. <year>2020</year>;<volume>8</volume>: <fpage>13</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/vaccines8010013</pub-id><?supplied-pmid 31906351?><pub-id pub-id-type="pmid">31906351</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref056">
      <label>56</label>
      <mixed-citation publication-type="journal"><name><surname>Zhou</surname><given-names>T</given-names></name>, <name><surname>Zhu</surname><given-names>J</given-names></name>, <name><surname>Wu</surname><given-names>X</given-names></name>, <name><surname>Moquin</surname><given-names>S</given-names></name>, <name><surname>Zhang</surname><given-names>B</given-names></name>, <name><surname>Acharya</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies</article-title>. <source>Immunity</source>. <year>2013</year>;<volume>39</volume>: <fpage>245</fpage>–<lpage>258</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.immuni.2013.04.012</pub-id><?supplied-pmid 23911655?><pub-id pub-id-type="pmid">23911655</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref057">
      <label>57</label>
      <mixed-citation publication-type="journal"><name><surname>West</surname><given-names>AP</given-names></name>, <name><surname>Diskin</surname><given-names>R</given-names></name>, <name><surname>Nussenzweig</surname><given-names>MC</given-names></name>, <name><surname>Bjorkman</surname><given-names>PJ</given-names></name>. <article-title>Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120</article-title>. <source>PNAS</source>. <year>2012</year>;<volume>109</volume>: <fpage>E2083</fpage>–<lpage>E2090</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1073/pnas.1208984109</pub-id><?supplied-pmid 22745174?><pub-id pub-id-type="pmid">22745174</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref058">
      <label>58</label>
      <mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>X</given-names></name>, <name><surname>Kong</surname><given-names>X-P</given-names></name>. <article-title>Antigenic landscape of the HIV-1 envelope and new immunological concepts defined by HIV-1 broadly neutralizing antibodies</article-title>. <source>Current Opinion in Immunology</source>. <year>2016</year>;<volume>42</volume>: <fpage>56</fpage>–<lpage>64</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.coi.2016.05.013</pub-id><?supplied-pmid 27289425?><pub-id pub-id-type="pmid">27289425</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref059">
      <label>59</label>
      <mixed-citation publication-type="journal"><name><surname>Bolen</surname><given-names>CR</given-names></name>, <name><surname>Rubelt</surname><given-names>F</given-names></name>, <name><surname>Vander Heiden</surname><given-names>JA</given-names></name>, <name><surname>Davis</surname><given-names>MM</given-names></name>. <article-title>The Repertoire Dissimilarity Index as a method to compare lymphocyte receptor repertoires</article-title>. <source>BMC Bioinformatics</source>. <year>2017</year>;<volume>18</volume>: <fpage>155</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12859-017-1556-5</pub-id><?supplied-pmid 28264647?><pub-id pub-id-type="pmid">28264647</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref060">
      <label>60</label>
      <mixed-citation publication-type="journal"><name><surname>Barnes</surname><given-names>CO</given-names></name>, <name><surname>Jette</surname><given-names>CA</given-names></name>, <name><surname>Abernathy</surname><given-names>ME</given-names></name>, <name><surname>Dam</surname><given-names>K-MA</given-names></name>, <name><surname>Esswein</surname><given-names>SR</given-names></name>, <name><surname>Gristick</surname><given-names>HB</given-names></name>, <etal>et al</etal>. <article-title>SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies</article-title>. <source>Nature</source>. <year>2020</year>; 1–6. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41586-020-2852-1</pub-id><?supplied-pmid 33045718?><pub-id pub-id-type="pmid">33045718</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref061">
      <label>61</label>
      <mixed-citation publication-type="journal"><name><surname>Barnes</surname><given-names>CO</given-names></name>, <name><surname>West</surname><given-names>AP</given-names></name>, <name><surname>Huey-Tubman</surname><given-names>KE</given-names></name>, <name><surname>Hoffmann</surname><given-names>MAG</given-names></name>, <name><surname>Sharaf</surname><given-names>NG</given-names></name>, <name><surname>Hoffman</surname><given-names>PR</given-names></name>, <etal>et al</etal>. <article-title>Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies</article-title>. <source>Cell</source>. <year>2020</year>;<volume>182</volume>: <fpage>828</fpage>–<lpage>842.e16</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cell.2020.06.025</pub-id><?supplied-pmid 32645326?><pub-id pub-id-type="pmid">32645326</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref062">
      <label>62</label>
      <mixed-citation publication-type="journal"><name><surname>Greiff</surname><given-names>V</given-names></name>, <name><surname>Bhat</surname><given-names>P</given-names></name>, <name><surname>Cook</surname><given-names>SC</given-names></name>, <name><surname>Menzel</surname><given-names>U</given-names></name>, <name><surname>Kang</surname><given-names>W</given-names></name>, <name><surname>Reddy</surname><given-names>ST</given-names></name>. <article-title>A bioinformatic framework for immune repertoire diversity profiling enables detection of immunological status</article-title>. <source>Genome Medicine</source>. <year>2015</year>;<volume>7</volume>: <fpage>49</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s13073-015-0169-8</pub-id><?supplied-pmid 26140055?><pub-id pub-id-type="pmid">26140055</pub-id></mixed-citation>
    </ref>
    <ref id="pcbi.1010052.ref063">
      <label>63</label>
      <mixed-citation publication-type="journal"><name><surname>Rognes</surname><given-names>T</given-names></name>, <name><surname>Scheffer</surname><given-names>L</given-names></name>, <name><surname>Greiff</surname><given-names>V</given-names></name>, <name><surname>Sandve</surname><given-names>GK</given-names></name>. <article-title>CompAIRR: ultra-fast comparison of adaptive immune receptor repertoires by exact and approximate sequence matching</article-title>. <source>Bioinformatics</source>. <year>2022</year>; <fpage>btac505</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/bioinformatics/btac505</pub-id><?supplied-pmid 35852318?><pub-id pub-id-type="pmid">35852318</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
<sub-article article-type="aggregated-review-documents" id="pcbi.1010052.r001" specific-use="decision-letter">
  <front-stub>
    <article-id pub-id-type="doi">10.1371/journal.pcbi.1010052.r001</article-id>
    <title-group>
      <article-title>Decision Letter 0</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>De Boer</surname>
          <given-names>Rob J.</given-names>
        </name>
        <role>Section Editor</role>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yaari</surname>
          <given-names>Gur</given-names>
        </name>
        <role>Guest Editor</role>
      </contrib>
    </contrib-group>
    <permissions>
      <copyright-statement>© 2022 De Boer, Yaari</copyright-statement>
      <copyright-year>2022</copyright-year>
      <copyright-holder>De Boer, Yaari</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <related-article ext-link-type="doi" xlink:href="10.1371/journal.pcbi.1010052" id="rel-obj001" related-article-type="reviewed-article"/>
    <custom-meta-group>
      <custom-meta>
        <meta-name>Submission Version</meta-name>
        <meta-value>0</meta-value>
      </custom-meta>
    </custom-meta-group>
  </front-stub>
  <body>
    <p>
      <named-content content-type="letter-date">18 Jun 2022</named-content>
    </p>
    <p>Dear Dr. Waltari,</p>
    <p>Thank you very much for submitting your manuscript "AIRRscape: an interactive tool for exploring B-cell receptor repertoires and antibody responses" for consideration at PLOS Computational Biology.</p>
    <p>As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers' comments.</p>
    <p>We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation.</p>
    <p>When you are ready to resubmit, please upload the following:</p>
    <p>[1] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.</p>
    <p>[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).</p>
    <p>Important additional instructions are given below your reviewer comments.</p>
    <p>Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.</p>
    <p>Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.</p>
    <p>Sincerely,</p>
    <p>Gur Yaari</p>
    <p>Guest Editor</p>
    <p>PLOS Computational Biology</p>
    <p>Rob De Boer</p>
    <p>Deputy Editor</p>
    <p>PLOS Computational Biology</p>
    <p>***********************</p>
    <p>Reviewer's Responses to Questions</p>
    <p>
      <bold>Comments to the Authors:</bold>
    </p>
    <p>
      <bold>Please note here if the review is uploaded as an attachment.</bold>
    </p>
    <p>Reviewer #1: Provided as an attachment</p>
    <p>Reviewer #2: See attachment.</p>
    <p>Reviewer #3: Review is uploaded as an attachment.</p>
    <p>Reviewer #4: This manuscript describes AIRRscape, an R Shiny application that can be run in the browser, and that allows for the comparison of antibody sequences based on V and J gene, and CDR3 length. It visualizes these antibody characteristics in the form of heatmaps and can examine the convergence of clonotypes by constructing phylogenetic-like trees. The three use cases illustrate potential applications of the tool. The source code is publicly available on GitHub. With the major comments addressed, especially concerning how it compares to other similar tools, I think AIRRscape could be a useful contribution to the field, particularly for researchers with less programming experience.</p>
    <p>Major comments:</p>
    <p>- Please provide an overview table of what new or improved functionality AIRRscape provides compared to other existing tools for antibody analyses, such as VDJtools <ext-link xlink:href="https://doi.org/10.1371/journal.pcbi.1004503" ext-link-type="uri">https://doi.org/10.1371/journal.pcbi.1004503</ext-link>, immunarch <ext-link xlink:href="http://doi.org/10.5281/zenodo.3367200" ext-link-type="uri">http://doi.org/10.5281/zenodo.3367200</ext-link>, PASA <ext-link xlink:href="https://doi.org/10.1371/journal.pcbi.1008607" ext-link-type="uri">https://doi.org/10.1371/journal.pcbi.1008607</ext-link>.</p>
    <p>- Please update Figure 1 to show an overview of all types of AIRR analyses that are possible in AIRRscape.</p>
    <p>- How are motifs defined and how are they discovered (e.g., line 64)? In line 203, the authors mention “healthy control motifs” – what does this mean? Please include the definitions and explanations of motifs in the manuscript.</p>
    <p>- In multiple places throughout the manuscript, the authors mention the increasing size of the antibody repertoires and how AIRRscape can help. For example, the author summary (line 27) states: “With AIRRscape, we enable large-scale immune repertoire visualization and analysis...”. How scalable is it? Please quantify scalability.</p>
    <p>Minor comments:</p>
    <p>- R and R studio versions are missing, along with dependencies. It would be nice to have all that resolved automatically if possible or to have a list of required packages and tools with versions. With this resolved, AIRRscape worked well locally for me.</p>
    <p>- The authors mention “processed flat files” multiple times (e.g., line 142): what does flat refer to in this context?</p>
    <p>- In line 172, it says that users may choose to construct the topology via either neighbor-joining or parsimony tree building methods. Is this performed using some package or is it a native AIRRscape implementation?</p>
    <p>**********</p>
    <p>
      <bold>Have the authors made all data and (if applicable) computational code underlying the findings in their manuscript fully available?</bold>
    </p>
    <p>The <ext-link xlink:href="https://journals.plos.org/ploscompbiol/s/materials-and-software-sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data and code underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data and code should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data or code —e.g. participant privacy or use of data from a third party—those must be specified.</p>
    <p>Reviewer #1: Yes</p>
    <p>Reviewer #2: Yes</p>
    <p>Reviewer #3: Yes</p>
    <p>Reviewer #4: Yes</p>
    <p>**********</p>
    <p>PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/ploscompbiol/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
    <p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
    <p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.</p>
    <p>Reviewer #1: No</p>
    <p>Reviewer #2: <bold>Yes: </bold>Krishna M. Roskin</p>
    <p>Reviewer #3: No</p>
    <p>Reviewer #4: No</p>
    <p>
      <underline>Figure Files:</underline>
    </p>
    <p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <underline><ext-link xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com</ext-link></underline>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <underline><email>figures@plos.org</email></underline>.</p>
    <p>
      <underline>Data Requirements:</underline>
    </p>
    <p>Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example in PLOS Biology see here: <ext-link xlink:href="http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5" ext-link-type="uri">http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5</ext-link>.</p>
    <p>
      <underline>Reproducibility:</underline>
    </p>
    <p>To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at <ext-link xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link></p>
    <supplementary-material id="pcbi.1010052.s002" position="float" content-type="local-data">
      <label>Attachment</label>
      <caption>
        <p>Submitted filename: <named-content content-type="submitted-filename">airrscape review.docx</named-content></p>
      </caption>
      <media xlink:href="pcbi.1010052.s002.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pcbi.1010052.s003" position="float" content-type="local-data">
      <label>Attachment</label>
      <caption>
        <p>Submitted filename: <named-content content-type="submitted-filename">AIRRscape.docx</named-content></p>
      </caption>
      <media xlink:href="pcbi.1010052.s003.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pcbi.1010052.s004" position="float" content-type="local-data">
      <label>Attachment</label>
      <caption>
        <p>Submitted filename: <named-content content-type="submitted-filename">2022-AIRRscape- an interactive tool for exploring B-cell receptor repertoires and antibody responses.docx</named-content></p>
      </caption>
      <media xlink:href="pcbi.1010052.s004.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </body>
</sub-article>
<sub-article article-type="author-comment" id="pcbi.1010052.r002">
  <front-stub>
    <article-id pub-id-type="doi">10.1371/journal.pcbi.1010052.r002</article-id>
    <title-group>
      <article-title>Author response to Decision Letter 0</article-title>
    </title-group>
    <related-article ext-link-type="doi" xlink:href="10.1371/journal.pcbi.1010052" id="rel-obj002" related-article-type="editor-report"/>
    <custom-meta-group>
      <custom-meta>
        <meta-name>Submission Version</meta-name>
        <meta-value>1</meta-value>
      </custom-meta>
    </custom-meta-group>
  </front-stub>
  <body>
    <p>
      <named-content content-type="author-response-date">5 Aug 2022</named-content>
    </p>
    <supplementary-material id="pcbi.1010052.s005" position="float" content-type="local-data">
      <label>Attachment</label>
      <caption>
        <p>Submitted filename: <named-content content-type="submitted-filename">AIRRScape reviews and reponses.docx</named-content></p>
      </caption>
      <media xlink:href="pcbi.1010052.s005.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </body>
</sub-article>
<sub-article article-type="aggregated-review-documents" id="pcbi.1010052.r003" specific-use="decision-letter">
  <front-stub>
    <article-id pub-id-type="doi">10.1371/journal.pcbi.1010052.r003</article-id>
    <title-group>
      <article-title>Decision Letter 1</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>De Boer</surname>
          <given-names>Rob J.</given-names>
        </name>
        <role>Section Editor</role>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yaari</surname>
          <given-names>Gur</given-names>
        </name>
        <role>Guest Editor</role>
      </contrib>
    </contrib-group>
    <permissions>
      <copyright-statement>© 2022 De Boer, Yaari</copyright-statement>
      <copyright-year>2022</copyright-year>
      <copyright-holder>De Boer, Yaari</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <related-article ext-link-type="doi" xlink:href="10.1371/journal.pcbi.1010052" id="rel-obj003" related-article-type="reviewed-article"/>
    <custom-meta-group>
      <custom-meta>
        <meta-name>Submission Version</meta-name>
        <meta-value>1</meta-value>
      </custom-meta>
    </custom-meta-group>
  </front-stub>
  <body>
    <p>
      <named-content content-type="letter-date">4 Sep 2022</named-content>
    </p>
    <p>Dear Dr. Waltari,</p>
    <p>We are pleased to inform you that your manuscript 'AIRRscape: an interactive tool for exploring B-cell receptor repertoires and antibody responses' has been provisionally accepted for publication in PLOS Computational Biology.</p>
    <p>Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests. Also, please address the minor commnets raised by reviewer #4 (see below).</p>
    <p>Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.</p>
    <p>IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.</p>
    <p>Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.</p>
    <p>Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Computational Biology. </p>
    <p>Best regards,</p>
    <p>Gur Yaari</p>
    <p>Guest Editor</p>
    <p>PLOS Computational Biology</p>
    <p>Rob De Boer</p>
    <p>Section Editor</p>
    <p>PLOS Computational Biology</p>
    <p>***********************************************************</p>
    <p>Reviewer's Responses to Questions</p>
    <p>
      <bold>Comments to the Authors:</bold>
    </p>
    <p>
      <bold>Please note here if the review is uploaded as an attachment.</bold>
    </p>
    <p>Reviewer #1: The points raised in my review have been addressed. Improvements to the scripts and provision of a web-based facility significantly improve usability for the average user.</p>
    <p>Reviewer #3: None. Authors have responded to all comments.</p>
    <p>Reviewer #4: The authors have successfully addressed the comments I had.</p>
    <p>Some very minor points:</p>
    <p>- Updating the added Table 1 to emphasize the main advantages of AIRRscape might make it clearer to readers why they should use AIRRscape and not some of the other tools listed, for a specific analysis, e.g., easier to use, visualization options.</p>
    <p>- While this information is now available in README under the Tips heading, having a very short description or table title for the two tables in the AIRRscape tab might make it more user-friendly.</p>
    <p>**********</p>
    <p>
      <bold>Have the authors made all data and (if applicable) computational code underlying the findings in their manuscript fully available?</bold>
    </p>
    <p>The <ext-link xlink:href="https://journals.plos.org/ploscompbiol/s/materials-and-software-sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data and code underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data and code should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data or code —e.g. participant privacy or use of data from a third party—those must be specified.</p>
    <p>Reviewer #1: Yes</p>
    <p>Reviewer #3: Yes</p>
    <p>Reviewer #4: Yes</p>
    <p>**********</p>
    <p>PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/ploscompbiol/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
    <p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
    <p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.</p>
    <p>Reviewer #1: No</p>
    <p>Reviewer #3: No</p>
    <p>Reviewer #4: No</p>
  </body>
</sub-article>
<sub-article article-type="editor-report" id="pcbi.1010052.r004" specific-use="acceptance-letter">
  <front-stub>
    <article-id pub-id-type="doi">10.1371/journal.pcbi.1010052.r004</article-id>
    <title-group>
      <article-title>Acceptance letter</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>De Boer</surname>
          <given-names>Rob J.</given-names>
        </name>
        <role>Section Editor</role>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yaari</surname>
          <given-names>Gur</given-names>
        </name>
        <role>Guest Editor</role>
      </contrib>
    </contrib-group>
    <permissions>
      <copyright-statement>© 2022 De Boer, Yaari</copyright-statement>
      <copyright-year>2022</copyright-year>
      <copyright-holder>De Boer, Yaari</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <related-article ext-link-type="doi" xlink:href="10.1371/journal.pcbi.1010052" id="rel-obj004" related-article-type="reviewed-article"/>
  </front-stub>
  <body>
    <p>
      <named-content content-type="letter-date">15 Sep 2022</named-content>
    </p>
    <p>PCOMPBIOL-D-22-00462R1 </p>
    <p>AIRRscape: an interactive tool for exploring B-cell receptor repertoires and antibody responses</p>
    <p>Dear Dr Waltari,</p>
    <p>I am pleased to inform you that your manuscript has been formally accepted for publication in PLOS Computational Biology. Your manuscript is now with our production department and you will be notified of the publication date in due course.</p>
    <p>The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. </p>
    <p>Soon after your final files are uploaded, unless you have opted out, the early version of your manuscript will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.</p>
    <p>Thank you again for supporting PLOS Computational Biology and open-access publishing. We are looking forward to publishing your work! </p>
    <p>With kind regards,</p>
    <p>Olena Szabo</p>
    <p>PLOS Computational Biology | Carlyle House, Carlyle Road, Cambridge CB4 3DN | United Kingdom <email>ploscompbiol@plos.org</email> | Phone +44 (0) 1223-442824 | <ext-link xlink:href="http://ploscompbiol.org" ext-link-type="uri">ploscompbiol.org</ext-link> | @PLOSCompBiol</p>
  </body>
</sub-article>
